AU657330B2 - Benzomorphan derivatives - Google Patents

Benzomorphan derivatives Download PDF

Info

Publication number
AU657330B2
AU657330B2 AU18686/92A AU1868692A AU657330B2 AU 657330 B2 AU657330 B2 AU 657330B2 AU 18686/92 A AU18686/92 A AU 18686/92A AU 1868692 A AU1868692 A AU 1868692A AU 657330 B2 AU657330 B2 AU 657330B2
Authority
AU
Australia
Prior art keywords
benzomorphan
trimethyl
hydroxy
hydrochloride
title compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU18686/92A
Other versions
AU1868692A (en
Inventor
Adrian Carter
Helmut Ensinger
Matthias Grauert
Franz Josef Kuhn
Herbert Merz
Enzio Muller
Werner Stransky
Ilse Streller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Publication of AU1868692A publication Critical patent/AU1868692A/en
Application granted granted Critical
Publication of AU657330B2 publication Critical patent/AU657330B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D221/00Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22Bridged ring systems
    • C07D221/26Benzomorphans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Benzomorphane derivs. of formula (I) are new. In (I), X = O or S; R1 = 1-8C alkyl, 3-6C alkenyl, 3-6C alkynyl or aryl; R2 = H, 1-8C alkyl, 3-6C alkenyl, 3-6C alkynyl, aryl or aralkyl; R3 = H or 1-6C alkyl; R4 and R5 = each 1-8C alkyl; R6 = 1-8C alkyl or aryl; R7 and R8 = each H, 1-8C alkyl, halogen, OH, 1-8C alkoxy, O-Acyl, CN, NO2, NH2, NH(1-8C alkyl), N(1-8C alkyl)2 (n which the alkyl gps. are opt. different), NH-acyl or N-acyl-(1-8C alkyl).

Description

P/00/01 1 Regutation 3.2
AUSTRALIA
PATENTS ACT 1990 657330 COMPLETE SPECIFICATION FOR A STANDARD PATENT
ORIGINAL
*9*S S S *5S* .5 S S 5S *5*S
S
*5 S S *5*e .9.
S* TO BE COMPLETED BY APPLICANT .Name of Applicant BOEHRINGER INGELHEIM INTERNATIONAL GmbH Actual Inventor(s): Adrian CARTER; Helmut ENSINGER; Matthias GRAUERT; Franz Josef KUHN, Herbert MERZ; Enzio MULLER, Werner STRANSKY and Use
STRELLER
Address for Service: CALLINAN LAWRIE, 278 High Street, Kew, 3101, Victoria, Australia Invention Title: "BENZOMORPHAN DERIVATIVES" The following statement is a full description of this invention, including the best method of performing it known to me:-, 1 Vi- 58153.34 Benzomorphan derivatives The present invention relates to new benzomorphan derivatives, to processes for their preparation and to their use as pharmaceutical compositions.
According to the present invention we provide compounds of general formula R1
N-CH
2
-C-X-R
2 rR 3 25 o* o 35 wherein X represents an oxygen or sulphur atom;
R
1 represents a C 1 _g-alkyl, C 3 6 -alkenyl, C 3 6 alkynyl or aryl group;
R
2 represents a hydrogen atom or a Ci,.-alkyl, C 3 6 alkenyl, C 3 6 -alkynyl, aryl or aralkyl group; 3 represents a hydrogen atom or a C 1 6 -alkyl group;
R
4 represents a C 1 .g-alkyl group;
R
5 represents a Ci.-alkyl group;
R
6 represents a C.-s-alkyl or aryl group; and
R
7 and R 8 which may be identical or different, V t I t i 1 IJ- W6 I Giw each repre ;ent a. hy-drogen or. halog'en- atct -OR,~k1 Cj_-aIcoxy, -O-acyl24 -(M NZ VL-(tF18alkYl).-R acy 1 -N~c:_.-a1ky1) -acv-1, or -(Cjak4) 2 gr (wherein the aik-l roups may be identica Cliff ezent); and all racemic, An ntiomeric and. diasteeoma=~ JformEs thereof and MJLu=es thereof and cid addition Salts therE 'Of with the excention o~the racetmic f orms of comrmounds wherein
RI
1 represents a q~-2~J 3 -alkeny1' or C 3 -1 alkynwyl grup,]nd UV I fc ~Ijy I~j 0*
OV.
*.040 $.alp
P,
2 rerpresents a hl al.kenyl group;
R
3 representsa i Sroup; and drgert atom, C3,.-a-1lcyl orC 1 rnrgea. atom or a C,.
1 ,-a-iky R6 p.
7
R!,
and Rs both represent a ni~Lhyl grouip; and r-epresents a C -a0ky1 or 'phe-Tyl group; and renresents a h-rcelatom; and represents a hydxrogen. atom, a 2' -hydroxv or 21t- C,_-alkoxy crup; or2 -R 11 jC00 whereU repreentsa hyrogen atom,aC 1 krl pheavi, benzyl, lphenethyl or 3-pyridyl griu and
A'
I
I.
x represents 0.
~4r
I,
IN:
1~.
a Aixpec i _cally .s tat otewie thenezal d ef in it ions are used I n the ollo-wLng, sense: Cj,,-alkyl or CI.--alkyl Wnerallv represenus a strai-t Schainied or branched ihydr cron radical havin; 1. to: GI or 8 a-rboni atoms 37esnect-e- which may optionally bei substituted by one or taoir&halogen atoms preerlyl fluorine Waie-1 may be identical to one anot-her ordifferent. The following hydrocarbon radicals may ?pe~ mentioned by way of k-am le- methyl, ethyl' propyl 2.
mthylethyl (isopropyl) r butyl, 1 -methytpropyl, matthv propyl, 1,l1-dimeth 4ethyl, pezntvl, I-tk~thylbutv', 2-ekluv,3-fe-thylb ityl, z, I-&Ltethylp.ropyl, 1!:2 dmtylpropyl, 2,2-d3_ e yrpy l 2-athvlpr I I 1 haexyl, 1-tnethy3-pe-ntyl 2-4methylpantyl, 3-uiethrjlpent-yl,meth23Vlpentyl, lil-c.med~IylbutyI,. 1,2-dimethylbuty-L-, 1,3 -dirnethylbutyl, 212 hy 3,3dimtI~~bu'V1, -eth butyl, 2-ethylbu-Z::,l, 1,1,2 *.trimet]ayipropyl, 1,2,2-tammethylpropylr- 1-ethyl-..- 20 methy]lpropyl anad 1-Gth-yl L-iethyl-propyl- Unless otherwise stated, lower ylGroups, having -l to 3 carbon atoms stich as met ethyl, propyl or isopropyl 25 alkenyl in general reore. ents a str-aight -chained or:
.V.
branched hydrocarbon ra-cal ha~ving 3 to 6 carbon atoms,
TC*
-3 and one or more, preferably one double bond which may optionally be substituted by one halogen atom or several halogen atoms, preferably fluorine, which may be identical to one another or different. Examples include: 2-propenyl (allyl), 2-butenyl, 3-butenyl, 1methyl1-2-propenyl, 2-methyl-2-propenyl, 2-pentenyl, 3pentenyl, 4-pentenyl, l-methyl-2-butenyl, 2-methyl-2butenyl, 3-methyl-2-butenyl, l-methyl-3-butenyl, 2methyl-3-;butenyl, 3-methyl-3-,butenyl, 1, l-dimethyl-2propenyli 1, 2-dimethyl-2-propenyl, l-ethyl-2-propenyl, 2-hexenyl,, 3-hexenyl, 4-hexenyl, 5-hexenyl, l-methyl-2pentenyl, 2-methyl-2-pentenyl, 3-methyl-2-pentenyl, 4- 0methyl-2--penteny 1, l-methyl-3-pentenyl, 2-methyl-3pentenyl, 3-methyl-3-pentenyl, 4-methyl-,3-pentenyl, 1methyl-4-pentenyl, 3-methyl-4-pentenyl, 4-methyl-4pentenyl, 1, l-dimethyl-2-butenyl, 1, l-dimethyl-3butenyl, 1, 2-dimethyl-2-butenyl, 1, 2-diineth-7l-3-butenyl, 1,3-dimethyl--2-butenyl, l,3-dimethyl-3-butenyl, 2,2dimethyl-3-butenyl, 2,3-dimethyl--2-butenyl, 2,3- 20 dimethyl-3-butenyl, l-ethyl-2-butenyl, l-ethyl-3butenyl, 2-ethyl-l-butenyl, 2-ethyl-2--butenyl, 2- ,"-iyl- .sees:3-butenyl, 1,1, 2-trimethyl-2-propenyl, 1-ethyl-i-methyl- 2-propenyl and l-ethyl-2-methyl-2-propenyl. The allyl group is preferred.
Alkynyl in general represents a straight-chained or branched hydrocarbon radical having 3 to 6 carbon atoms and one or more triple bonds. A lower alkynyl radical (propargyl) having 3 carbon atoms and a triple bond which may optionally be substituted by a halogen atoral preferably fluorine or several halogen atoms which may be identical to one another or different is preferred.
Acyl in general represents bei-ioyl or alkylcarbonyl radicals such as straight-chained or branched lower alkyl having from 1 to about 6 carbon, atoms bound via a carbonyl group, the alkyl radical optionally being 4 substituted by one or more halogen atoms, which may be identical to one another or different. Alkyl groups having up to 4 carbon atoms are preferred. Examples include: acetyl, trifluoroacetyl, ethylcarbonyl, propylcarbonyl, isopropylcarbonyl, butylcarbonyl and isobutylcarbonyl. The acetyl group is particularly preferred.
Acyloxy denotes an acyl group bound via an oxygen atom, acyl being defined as hereinbefore.
Aryl in general represents an aromatic radical having 6 to 10 carbon atoms also in combinations, it being possible for the aromatic ring to be substituted by one or more lower alkyl group(s), alkoxy group(s), nitro group(s), amino group(s) and/or one or more halogen atomt(s) which are identical to one another or different. The preferred aryl group is phenyl.
20 Aralkyl in general represents an aryl radical having 7 to 14 carbon atoms which is bonded via an alkylene chain, it being possible for the aromatic ring to be substituted by one or more lower alkyl group(s), alkoxy group(s), nitro group(s), amino group(s) and/or one or 25 more halogen atom(s) which are identical to one another or different. Aralkyl radicals having 1 to 6 carbon atoms in the aliphatic part and 6 to 10 carbon atoms in the aromatic part are preferred. Preferred 2* aralkyl radicals which may be mentioned unless otherwise stated are: benzyl, phenethyl and *phenylpropyl.
Alkoxy in general represents a straight-chain or branched hydrocarbon radical having 1 to 8 carbon atoms which is bonded via an oxygen atom. A lower alkoxy radical having 1 to 3 carbon atoms is preferred. The methoxy group is particularly preferred.
5 Unless otherwise stated, amino represents an NH 2 -function which may optionally be substituted by one or two Ci.alkyl, aryl or aralkyl groups, either identical or different.
Alkylamino, for example, denotes methylamino, ethylamino, propylamino, 1-methylethylamino, butylamino, 1-methylpropylamino, 2-methylpropylamino or 1,1dimethylethylamino.
Dialkylamino, for example, denotes dimethylamino, O diethylamino, dipropylamino, dibutylamino, di-(lmethylethyl)amino, di-(l-methylpropyl)amino, di-2methylpropylamino, ethylmethylamino or methylpropylamino.
Unless stated otherwise, halogen primarily represents fluorine, chlorine and bromine and, to a lesser degree, iodine.
Compounds according to the present invention which are preferred include compounds of general formula (I) wherein 25 X represents an oxygen or sulphur atom;
R
1 represents a methyl, ethyl, propyl, isopropyl or phenyl group;
R
2 represents a methyl, ethyl, propyl, isopropyl, allyl, propargyl, phenyl or benzyl group;
R
3 represents a hydrogen atom or a C 1 alkyl group;
R
4 represents a methyl, ethyl, propyl or isopropyl group; 6
R
5 represents a methyl, ethyl, propyl or isopropyl group;
R
6 represents a methyl, ethyl, propyl, isopropyl ,or phenyl group;
R
7 represents a fluorine or chlorine atom or a hydroxy, lower alkyl, lower alkoxy or acyloxy group; and
R
8 represents a hydrogen atom or a lower alkyl, hydroxy or alkoxy group; and all racemic, enantiomeric and diastereomeric forms thereof and mixtures thereof and acid addition salts thereof.
Compounds according to the present invention which are particularly preferred include compounds of general 20 formula wherein S* 4 X represents an oxygen atom;
R
1 represents a methyl or ethyl group;
R
2 represents a methyl or ethyl group; 3
SR
3 represents a hydrogen atom;
R
4 represents a methyl or ethyl group; Goo
R
5 represents a methyl or ethyl group;
R
6 represents a methyl or ethyl group;
R
7 represents a hydroxy, methyl, methoxy or acyloXy group; and
S
7
R
8 represents a hydrogen atom or a methyl, ethyl, hydroxy or lower alkoxy group; and all racemic, enantiomeric and diastereomeric forms thereof and mixtures thereof and acid addition salts thereof.
Compounds according to the present invention which are more particularly preferred are compounds of general formula wherein X represents an oxygen atom;
R
1 represents a methyl group;
R
2 represents a methyl group;
R
3 represents a hydrogen atom; 20 R 4 represents a methyl group;
R
5 represents a methyl group;
R
6 represents a methyl group;
R
7 represents a hydroxy, methyl, methoxy or acetoxy group; and
R
8 represents a hydrogen atom or a methyl, 30 hydroxy, methoxy or ethoxy group; and all racemic, enantiomeric and diastereomeric forms thereof and mixtures thereof and acid addition salts thereof; especially preferred being those in which the substituents R 7 and R 8 are in the 2'-position and 3'-
S
S S SS S S 8 position respectively and the 2"-carbon atom has the Rconfiguration.
The numbering of the positions in the compounds of formula is as follows: R1
N-CH
2
-C--X-R
2
R
3 f~ R 4 108 9
R
6 21 7 The present invention relates to the individual isomers, mixtures thereof and the corresponding physiologically suitable acid addition salts of the compounds of formula with inorganic or organic acids. Examples of preferred salts are those with hydrochioric acid, hydrobromic acid, sulphuric acid, phosphoric acid, 20 methanesulphonic acid, ethanesulphonic acid, S. toluenesulphonic acid, benzenesulphonic acid, lactic acid, malonic acid, succinic acid, maleic acid, fumaric acid, malic acid, tartaric acid, citric acid or benzoic acid.
1. Methods of synthesis The compounds according to the present invention may be prepared by a variety of processes.
According to a further aspect of the present invention we provide a process for the preparation of a compound of general formula as hereinbefore defined wherein either a) a compound of general formula (wherein R 4
R
9 and P.
6 are as defined hereinbefore and R 9 and R 1 0 are either as defined hereinbefore for R 7 and R 8 or represent groups which can be converted into the latter in a known manner) is reacted with a carboxylic acid derivative of general formula (4) (wherein Y represents a leaving group, capable of being substituted by a secondary amino group, and
R
1
R
2
R
3 and X are as defined hereinbefore) 0 R' 8-iiR 2 N R6 N-H iR--
X
4 R3 R R 6 (3) and the resulting acid amide of formula is subsequently reduced to obtain the amine of general formula (6) 2
R
R 2 NCH2 X R
R
Rio RREt R3R 25 RR .6:60 R99 RR 7 6 S. (1 *0 and, where necessary, the substituents R 9 and R 10 as defined above are converted into R 7 and R 8 as 0* defined hereinbefore, and the compound of formula lthereby obtained is isolated; or b) a compound of general formula (2) 10 S2
R
Rio R Z-CH2 n RR RF R R 5 R9 R6 (6) (wherein R 4
R
5
R
6
R
9 and R 10 are as defined above in is reacted with an alkylating agent of general formula (wherein Z represents a leaving group, which can be substituted by a secondary amino group, and R 1
R
2
R
3 and X are as defined hereinbefore), to obtain the tertiary amine of formula R'
R
NCH2 R CH2 X^2 R R
-R"
1 Ri ~OR s R S R 9
R
6 RT R 6 (1) and, where necessary, the substituents R 9 and R 10 as defined above are converted into R 7 and R 8 as defined in claim 1, and the compound of formula (I) thereby obtained is isolated.
S*
Thus the compounds of formula according to the present invention may be prepared according to the 25 following reaction s" eme: R NCH2 X
R
0 N RR Rs Rio R R R R 9 R\ O R R R 6 Reduc- Y-oC R 3 R 2 R Z-CH 2 xo Rs R1 <CH25 R 3 R <o R R R6
R
9
R
6 (2 (6) (2) 11 The type 2 benzomorphan derivatives used as starting materials in this scheme are either prepared according to the prior art [DE-A 20 27 077, CA 74 (1971) 125482x; EP-B 4960, CA 93 (1980) 4941 f] or are prepared as described in the Examples given hereinafter.
The substituents R 9 and R 10 are either identical to the desired substituents R 7 and R 8 or are converted into them in a later stage of synthesis.
l.la One way of introducing a desired substituent at the amino function of the benzomorphan nitrogen is to carry out acylation with a suitably activated carboxylic acid derivative. Corresponding carboxylic acid derivatives of type 4 are known from the prior art or are easily obtainable by current methods of synthesis.
O. Preferred leaving groups for the compounds of type 4 include, for example, halogen, hydroxy, OC(O)alkyl, Oacyl, OSO 2 alkyl and OSO 2 aryl.
25 For the acylation itself there Ire again a number of methods to choose from Ferr,, Reaktionen der organischen Synthese, Georg ThieM'e Verlag Stuttgart, 1978, p. 222 ff. and loc. cit. J. March, Advanced Organic Chemistry, 3rd Ed., John WSley and Sons, New 12 York 1985, p. 370 ff and loc. cit.; R.C. Larock, Comprehensive Organic Transformations A Guide to Functional Group Preparations, VCH Verlagsgesellschaft, D-6940 Weinheim 1989, p. 963 ff and loc. cit.], the preferred method being reactions with carboxylic acid halides Beckwith in J. Zabicki, "The Chemistry of Amides", Interscience, New York 1970 p. 73] in a solvent which is substantially inert under the reaction conditions prevailing, optionally in the presence of acid-binding agents. The inert solvents used are generally organic solvents which do not change under the reaction conditions used, such as hydrocarbons e.g.
benzene, toluene or xylene or petroleum fractions or ethers e.g. diethylether, glycoldimethylether (glyme), diglycoldimethylether or cyclic ethers e.g.
tetrahydrofuran or dioxane or halohydrocarbon e.g.
carbon tetrachloride, chloroform or dichloromethane.
The preparation of the desired carboxylic acid halides 20 is known from the prior art [Houben-Weyl, Methoden der organischen Chemie, Volume VIII and Volume E5, Georg Thieme Verlag, Stuttgart, 1952 and 1985] where they are not commercially obtainable. Conveniently, the benzomorphan derivative of type 2 is preferably reacted 25 in halogenated hydrocarbons, especially in dichloromethane, and in the presence of tertiary amines, such as triethylamine, with the desired acid halide, more especially with the desired acid chloride.
However, it is also possible to carry out the reaction according to the so-called Schotten-Baumann Variant in water or in an aqueous alcohol in the presence of alkali metal hydroxides or alkali metal carbonates [see for example Organikum, Autorenkollektiv, VEB Deutscher Verlag der Wissenschaften, 17th Edition, Berlin 1988 p. 407]. Depending on the educts used it has also proved particularly advantageous to carry out the acylation according to the Einhorn variant, in which 13 pyridine is used both as an acid-binding agent and as a reaction medium.
In addition, there is the possibility of carrying out the reaction of acylation with the free carboxylic acid [see for example A.L.J. Beckwith in J. Zabicki, "The Chemistry of Amides", Interscience, New York 1970, p.
105 ff; J.A. Mitchell and E.E. Reid, J. Am. Chem. Soc.
53 (1931) 1879]. It may also prove appropriate to use a mixed arnydride, e.g. with a carbonic acid ester, instead of the free carboxylic acid Ferri, Reaktionen der organischen Synhtese, Georg Thieme Verlag, Stuttgart 1978, p. 222 and loc. cit.; A.L.J.
Beckwith in J. Zabicki, "The Chemistry of Amides", Interscience, New York 1970, p. 86; J. March, Advanced Organic Chemistry, 3rd Ed., John Wiley and Sons, New York 1985, p. 371 and loc. cit., R.C. Larock, Comprehensive Organic Transformations, VCH Publishers, D-6940 Weinheim 1989, p. 981 and loc. cit.].
In the preferred acylation with carboxylic acid halides, :especially carboxylic acid chlorides, the reaction temperature may vary within wide limits, the lower limit being set by excessively slow reaction speeds whilst the 25 upper limit is set by the proliferation of undesirable secondary reactions. Reaction temperatures in the range from -50*C to 150°C, preferably from 0°C to 75°C, have proved suitable. The work is conveniently done with a slight excess of the acylating agent in the presence of an acid binding agent (present in a somewhat larger excess) to ensure that the educts are reacted as completely as possible.
1.lb In order to obtain the desired amine of type 6, it is necessary to reduce the acid amide 3 in the subsequent reaction step.
14 Reductions of acid amides of this kind are known from the prior art and may be carried out by electrolytic reduction, by reduction with alkali metals and by catalytic reduction Schr6ter in Houben-Weyl, Methoden der organischen Chemie, Volume XI/1, Georg Thieme Verlag, Stuttgart 1957, p. 574] or with diborane or borane derivatives Fuhrhop and G. Penzlin, Organic Synthesis Concepts Methods Starting Materials, VCH-Verlagsgesellschaft, Weinheim 1986, p. It is preferred to carry out the reduction with complex hydrides such as alkali metal borohydrides or alkali aluminium hydrides with suitable derivatives thereof, optionally in the presence of a catalyst Gaylord, Reduction with Complex Metal Hydrides, Wiley New York 1965; A. HAjos, Complex Hydrides, Elsevier New York 1979; V. Bafant, M. Capka, M. Cerny, V. Chvalovsky, K.
Kochloefl, M. Kraus und J. M&lek, Tetrahedron Lett. 9 20 (1968) 3303], lithium aluminium hydride being particularly preferred.
Suitable reaction media are all the inert organic solvents which do not change under the reaction .I 25 conditions specified. These preferably include ethers such as diethylether, diisopropylether, tert.butylmethylether, di-n-butylether, glycoldimethylether (glyme), diglycoldimethylether (diglyme), cyclic ethers such as dioxane and, particularly preferably, tetrahydrofuran, the choice of solvent being guided, *inter alia, by the particular reducing agent used.
It is generally advantageous to allow these reductions to proceed in the presence of an excess of the reducing agent, which preferably takes the form of one of the above-mentioned complex hydrides, particularly lithium alanate, in a range from 5 to 100%, preferably in the 15 range from 10 to The reactants are usually added whilst cooling with ice or at ambient temperature and then heated to temperatures in the region of 150*C, preferably up to depending on the reactivity of the educts.
1.2 Another possible method of preparing benzomorphan derivatives of type 6 is to react the benzomorphan derivative 2 with suitable alkylating agents of type in which Z in formula 5 represents a leaving group which leaves during the alkylation. Preferred leaving groups include, for example, halogen, such as Cl, Br and I, or O-SO2-aryl, such as tosylate, or an alkylsulphonate
O-SO
2 -alkyl, such as methanesulphonate, or halomethanesulphonate or sulphate. Corresponding alkylating reagents are either commercially obtainable or may be prepared by methods known in the art.
Suitable solvents include all inert solvents which iremain substantially unchanged under the reaction conditions specified and which, because they are not themselves reactive components, cannot have a negative 25 influence on the course of the reaction. Examples are alcohols, such as methanol, ethanol, propanol or isopropanol, or ethers, such as diethylether, di-nbutyl-ether, tert.butylmethylether, glycoldimethylether %move (glyme), diethyleneglycoldimethylether (diglyme), tetrahydrofuran and dioxane or ketones, such as methylethyl ketone or acetone, or acid amides, such as hexamethylphosphoric acid triamide or dimethylformamide.
It is also possible to use mixtures of the ,abovementioned solvents. Tetrahydrofuran or dimethylformamide or mixtures of these two solvents are 16 particularly preferred. The reaction is preferably carried out in the presence of acid-binding agents such as alkali or alkaline earth metal carbonates or hydrogen carbonates.
The reaction temperature may vary within wide limits in the course of the reaction, these limits being set by too slow a reaction rate, at the bottom of the scale, for practical purposes, and by a prevalence of side reactions, at the top of the scale. Suitable reaction temperatures fall within the range from 0°C to 150"C and O preferably from 50°C to 100°C.
1.3 The conversion of R 9 and/or R 10 into R 7 and R e respectively, which may be necessary, involves a number of different reactions, which cannot be illustrated in a single scheme. Such conversion reactions are described hereinafter in the corresponding Examples.
2. Pharmacological Characterisation
S
It is known that after systemic administration of glutamate, neurones are destroyed in mouse brains [S.M.
25 Rothman and T.W. Olney, Trends in Neurosciences (1987) 299]. This finding leads one to conclude, inter alia, that glutamate plays a part in neurodegenerative diseases Schwarcz and B. Meldrum, The Lancet 11 (1985) 140].
In addition, substances such as quisqualic acid, cainic acid, ibotenic acid, glutamic acid and N-methyl-Daspartic acid (NMDA) are known as exogenous or endogenous neurotoxins. In terms of their neurotoxicity these substances have a selective effect on individual types of cells, which means that loss of function can be induced in animals by specific brain lesions. This loss 17 of function is comparable with that which occurs in connection with epilepsy and other neurodegenerative diseases, such as Huntington's chorea and Alzheimer's disease.
Furthermore, tests carried out in vivo and in vitro have shown that the cell damage and loss of function occurring in the brain as a result of hypoglycaemia, hypoxia, anoxia and ischaemia are due to an increased synaptic activity, the glutamatergic synapse being particularly significant. Substances and ions which inhibit the activity of the glutamate receptor and the ion channel connected to this receptor such as competitive and non-competitive antagonists of excitatory amino acids as well as magnesium ions (Mg 2 protect the brain cells from hypoxic or ischaemic damage. These findings short that the glutamate receptor plays an important part in mediating ischaemic damage.
Biochemical and electrophysiological studies show that the receptor ion channel is highly sensitive to fluctuations in the magnesium concentration. If there is a fall in the magnesium concentration, spontaneous epileptic discharges are caused in the hippccampus, 25 which can be inhibited by antagonists of excitatory amino acids.
Surprisingly, it has now been found that benzomorphan derivatives of general formula block the NMDAchannel and have a neuroprotective activity.
The preparation of these benzomorphan derivatives is known from German Patent 21 05 743 and German Offenlegungsschrift 28 28 039 and from the literature Merz and K. Stockhaus, J. Med. Chem. 22. (1979) 1475]. It is also already known that compounds of this kind have an analgesic effect and can be used 18 therapeutically as non-addictive analgesics as well as antitussives (German Patent 21 05 743).
The hippocampal section is used as a test system for demonstrating the NMDA-antagonistic activity of the benzomorphan derivatives according to the present invention. The Schaffer collaterals of the hippocampal section in an infusion chamber are stimulated by means of microelectrodes and the total potentials occurring are derived extracellularly at the pyramidal cells of the CAI-region Haas, Schaerer and M. Vosmansky, J.
Neuroscience Meth. 1 (1979) 323].
The neuroprotective effect of the benzomorphan derivatives which fall within the scope of general formula was also demonstrated in relation to protein synthesis and the liberation of neurotransmitters in the hippocampal section.
Receptor binding tests also show that the benzomorphan derivatives disclosed are non-competitive glutamate receptor antagonists.
Furthermore, the neuroprotective activity of the 25 benzomorphan derivatives of general formula was tested on the mouse in vivo by inhibiting the lethality induced by N-methyl-D-aspartic acid [J.D.
Leander et al., Brain Research 448 (1988) 115] and by inhibiting the ischaemia-induced neuronal cell death in the mouse and gerbil.
These results, therefore, indicate that the compounds according to the present invention i.e. the benzomorphan derivatives of general formula are suitable for the prevention, treatment and repair of neurodegenerative diseases and conditions, epilepsy, cerebral ischaeinia of various origins and damage caised therefrom. These 19 include, for example: the epileptic state, hypoglycaemia, hypoxia, anoxia, brain trauma, brain oedema, atyobtropic lateral sclerosis, Huntington's disease, Alzheimer's disease, hypotonia, cardiac infarct, cerebral stroke and perinatal asphyxia.
3. Formulations According to a yet further aspect of the present invention there are provided pharmaceutical compositions comprising as active ingredient at least one compound of O formula as hereinbefore defined, in the form of a single enantiomer or diastereoisomer or mixtures thereof, or a physiologically acceptable acid addition salt thereof in association with one or more pharmaceutically acceptable carriers, diluents or excipients.
The benzomorphan derivatives of general formula and the acid addition salts thereof with pharmacologically acceptable acids may be converted in known manner into the usual formulations such as plain or coated tablets, pills, granules, aerosols, syrups, emulsions, suspensions and solutions, using inert pharmaceutically 25 acceptable carriers or solvents. The proportion of pharmaceutically active compounds should be within the range from 0.5 to 90 of the total composition, i.e. in amounts which are sufficient to achieve the dosage range specified below.
The formulations are prepared, for example, by diluting the active substances with solvents and/or carriers, optionally using emulsifiers and/or dispersing agents, whilst if water is used as the diluent, for example, organic solvents may be used as solubilisers or auxiliary solvents.
20 Examples of excipients include water, pharmaceutically acceptable organic solvents such as paraffins (e.g.
petroleum fractions), vegetable oils groundnut or sesame oil), mono- or polyfunctional alcohols (e.g.
ethanol or glycerol), carriers such as natural mineral powders kaolins, clays, talc, chalk), synthetic mineral powders highly dispersed silica and silicates), sugars glucose, lactose and fructose), emulsifiers lignin, sulphite waste lyse, methylcellulose, starch and polyvinylpyrrolidone) and lubricants magnesium stearate, talc, stearic acid and sodium laurylsulphate).
The preparations are administered in conventional manner, preferably by parenteral route, particularly by infusion, and intravenously. In the case of oral administration the tablets may, of course, contain in addition to the above-mentioned carriers additives such as sodium citrate, calcium carbonate and dicalcium phosphate together with various additional substances such as starch, preferably potato starch, gelatine and the like. In addition, lubricants such as magnesium stearate, sodium laurylsulphate and talc may be used in making the tablets. In the case of aqueous suspensions, 25 the active substances may be combined with various flavour improvers or colourings in addition to the *see excipients mentioned above.
o* For parenteral administration, solutions of the actirve substances may be prepared, using suitable liquid carriers.
The dosage for oral use is from 1 to 300 mg, preferably between 5 and 150 mg.
However, it may in some cases be necessary to deviate from the amounts specified, depending on the body weight 21 or method of administration, the individual response to the drug, the type of formulation and the time or period of time over which the preparation is administered.
Thus, in some eases, it may be sufficient to use less than the prescribed minimum whereas in other cases the upper limit must be exceeded. If larger quantities are administered it may be advisable to divide them into several smaller doses distributed over the day.
Furthermore, the compounds of general formula or the acid addition salts thereof may also be combined with O active substances of other kinds.
According to a yet further feature of the present invention there is provided a method of prevention, treatment or repair of neurogenerative diseases and conditions, of epilepsy, and of cerebral ischaemia of various origins in a subject which comprises administering to said subject an effective amount of a compound of formula as hereinbefore defined or a physiologically acceptable acid addition salt thereof.
.o The following Examples of formulations serve to further illustrate the present invention.
Tablets 1. The tablet contains the following ingredients: Active substance according to formula I 0.020 parts Stearic acid 0.010 Dextrose 1.890 Total 1.920 parts Preparation The substances are mixed together in known manner and the mixture is compressed to form tablets, each weighing 22 1.92 g and containing 20 mg of active substance.
Ampoule solution Composition Active substance according to formula I Sodium chloride Water for injection 1.0 mg 45.0 mg to 5.0 ml Preparation The active substance is dissolved in water at its own pH or possibly at pH 5.5 to 6.5 and sodium chloride is added to make the solution isotonic. The resulting 15 solution is filtered free from pyrogens and the filtrate is transferred under aseptic conditions into ampoules which are then sterilised and sealed by fusion. The ampoules contain 1 mg, 5 mg and 10 mg of active substance.
Suppositories Each suppository contains: Active substance according to formula I Cocoa butter (melting point: 36-37C) Carnauba wax 1.0 parts 1200.0 parts 5.0 parts
S
Preparation The cocoa butter and carnauba wax are melted together.
At 45°C the active substance is added and the mixture is stirred Until fully dispersed. The mixture is poured into suitably sized moulds and the suppositories are suitably packaged.
23 4. Examples The following non-limiting Examples serve to further illustrate the present invention: In the details which follow, unless otherwise stated, the word ether denotes diethylether.
4.1 Compounds of type prepared according to process 1.1 O 4.1.1 Example 1 (-)-(1R,5S,2"R)-2'-hydroxy-2-(2-methoxypropyl)-5,9,9-trimethyl-6,7-benzomorphan 15 hydrochloride a) Acylation 27.8 g (0.12 mol) of (±)-2'-hydroxy-5,9,9-trimethyl-6,7benzomorphan [DOS 20 27 077; CA 74, 125482x (1971)] are mixed with 278 ml of absolute dichloromethane in the presence of 27.9 g (0.275 mol) of triethylamine and 19.2 g (0.156 mol) of (R)-2-methoxypropionic acid chloride are added, with stirring, within about 25 minutes. The reaction temperature is maintained in the range from 30 to 35*C. The mixture is then refluxed for one hour. It is then cooled and washed successively *with 175 ml of water, 1.75 ml of 2 N hydrochloric acid and twice more with 175 ml of water. After drying with sodium sulphate and filtering off the drying agent the solution is evaporated down in vacuo, at a final temperature of 80 0 C under a full water jet vacuum. The acylation product of type is obtained as an evaporation residue in a yield of 42.3 g (around 100% of theory).
24 b) Reduction The acylation product prepared using the process described above is dissolved in 425 ml of absolute tetrahydrofuran. The solution is added dropwise, with stirring and cooling with ice, to a suspension of 9.1 g (0.24 mol) of lithium aluminium hydride (lithium tetrahydridoalanate) in 300 ml of tetrahydrofuran within one hour at 10 to 15*C. Then the reaction mixture is refluxed for two hours with stirring. 25 ml of water are then added dropwise thereto, whilst cooling in an ice bath and with stirring, and finally, after the addition of a further 70 ml of water and saturated diammonium tartrate solution (890 ml), the mixture is S 15 shaken in a separating funnel. The tetrahydrofuran phase separated off is evaporated down in vacuo and the aqueous phase is extracted three times with 175 ml of dichloromethane. The evaporation residue of the tetrahydrofuran phase is dissolved with the dichloromethane extracts and the solution is washed twice with 100 ml of water. After drying with sodium sulphate and removal of the drying agent by filtering, the solution is evaporated down, at a final temperature of 80°C under a full water jet vacuum. A residue 25 remains (37 g, about 100% of theory), which consists of a mixture of the two diastereomeric compounds expected.
In the thin layer chromatograph (TLC) these diastereomers show Rf values of 0.42 and 0.51 (silica gel 60, chloroform-methanol-conc. ammonia 95:5:0.1).
The diastereomers can be separated by crystallisation of the hydrochlorides. To do this, the basic mixture is dissolved in 120 ml of absolute ethanol and the solution is acidified with hydrochloric acid (12 ml 32% hydrochloric acid). The title compound (Rf 0.42) crystallises immediately, is cooled (ice bath), suction filtered, washed with ice cold ethanol (40 ml) in 25 batches and is dried, at a final temperature of until a constant weight is achieved. The yield is 15.0 g (73.5% of the maximum amount theoretically obtainable). The substance melts at 264°C with decomposition and has a specific optical rotation of -116.9° (c 1, CH 3 OH). A sample recrystallised from a mixture of methanol and diethylether melts at an unchanged melting point of 264*C (decomp.) and has a specific rotation of [a]25= -118.6° (c 1, CH 3
OH).
4.1.2 Example 2 (+)-(lS,5R,2"R)-2'-hydroxy-2-(2-methoxypropyl)-5,9,9-trimethyl-6,7-benzomorphan hydrochloride The mother liquor obtained in the process according to Example 1 contains predominantly the diastereomer with an Rf value of 0.51. It is evaporated down and the S..residue (25 g) is heated to reflux temperature with 40 ml of isopropanol for one hour with stirring. The crystal suspension thus obtained is left to stand at ambient temperature for about 12 hours, then suction filtered and washed in batches with a little cold isopropanol. The crystals consist mainly of the title 25 compound together with residues of the diastereomer (Example The title compound is converted into the free base form and purified by column chromatography.
For this purpose, the crystals are shaken with water (75 ml), dichloromethane (75 ml) and excess conc.
ammonia (25% strength, 6 ml). After separation of the phases the aqueous layer is extracted once more with ml of dichloromethane. The combined dichloromethane extracts are washed twice with 25 ml of water, then dried with sodium sulphate and, after removal of the drying agent by filtration, evaporated down at a final temperature of 80°C under a full water jet vacuum. The residue (15.4 g) is purified by column chromatography on 26 2 kg of silica gel (MN K 60, 230-400 mesh ASTM made by Macherey and Nagel) using dichloromethane-methanol-conc.
ammonia 95:5:0.1 as eluant. The fractions containing the pure substance yield a residue (6.8 g) after evaporation, consisting of the base of the title compound. The residue is dissolved with 14 ml of absolute ethanol and the solution is acidified with ml of 2.5 N ethanolic hydrochloric acid. After the addition of diethylether until the turbidity is just constant, the title compound crystallises out. The mixture is left to stand in the refrigerator for about d 12 hours and then suction filtered and washed first with an methanol-ether mixture 1:2 and then with ether.
After drying, finally at 80°C, 6.4 g of the title S 15 compound are obtained (31.4% of the maximum amount theoretically obtainable) with a melting point of 236°C (decomp.) and a specific rotation of [C] 5 +88.0" (c 1, CH 3
OH).
4.1.3 Example 3 (+)-(1S,5R,2"S)-2'-hydroxy-2-(2-methoxypropyl)-5,9,9-trimethyl-6,7-benzomorphan hydrochloride Starting from 9.25 g (0.040 mol) of (±)-2'-hydroxy- 5,9,9-trimethyl-6,7-benzomorphan and 6.37 g (0.052 mol) of (S)-2-methoxypropionic acid chloride, the title compound is obtained analogously to Example 1 in a yield of 5.1 g (75.0% of theory) with an Rf value of 0.42, a melting point of 270°C (decomp.) and a specific rotation of 2 5= +117° (c 1, CH 3
OH).
27 4.1.4 Example 4 (-)-(1R,5S,2"S)-2'-hydroxy-2-(2-methoxypropyl)-5,9,9-trimethyl-6,7-benzomorphan hydrochloride Starting from the mother liquor obtained in Example 3 the title compound is obtained analogously to Example 2 in a yield of 3.2 g (47.1% of theory) with a melting point of 235*C (decomp.) and a specific rotation of [a]25= -89.9° (c 1, CH 3
OH).
O 4.1.5 Example (-)-(1R,5S,2"R)-2'-hydroxy-2-(2-methoxypropyl)-5,9,9-trimethyl-6,7-benzomorphan 15 hydrochloride If instead of the racemic starting compound 2.31 g (0.010 mol) of the enantiomerically pure (-)-2'-hydroxy- 5,9,9-trimethyl-6,7-benzomorphan are reacted analogously to Example 1 with 1.60 g (0.013 mol) of methoxypropionic acid chloride, instead of a mixture of the diastereomeric bases the sterically pure base of the title compound will first be obtained and from this the hydrochloride is obtained in a yield of 3.0 g (88.4% of 25 theory) with a melting point of 264*C (decomp.) and a specific rotation of -117.5" (c 1, CH 3
OH).
4.1.6 Example 6 (-)-(1R,5S,2"S)-2'-hydroxy-2-(2-methoxypropyl)-5,9,9-trimethyl-6,7-benzomorphan hydrochloride If the synthesis described in Example 5 is carried out with (S)-2-methoxypropionic acid, the title compound is obtained in a yield of 2.9 g (85.3% of theory) with a melting point of 235 0 C (decomp.) and a specific rotation of [a] 5 -89.7 (c 1, CH 3
OH).
28 4.1.7 Example 7 (-)-(1R,5S,2"R)-2'-hydroxy-2-(2-methoxypropyl)-5,9,9-trimethyl-6,7-benzomorphan hydrochloride Starting from 4.62 g (0.020 mol) of (-)-2'-hydroxy- 5,9,9-trimethyl-6,7-benzomorphan and 3.20 g (0.026 mol) of (R/S)-2-methoxypropionic acid chloride, there is obtained analogously to Example 1 a mixture of the expected diastereomeric bases which are separated by column chromatography analogously to Example 2. The slower running substance (Rf 0.42) is crystallised as the hydrochloride as described therein. The title compound is obtained in a yield of 2.1 g (61.8% of theory) with a melting point of 264 0 C (decomp.) and a S. specific rotation of [a]25= -117.9" (c 1,
*D
4.1.8 Example 8 (-)-(1R,2S,2"S)-2'-hydroxy-2-(2-methoxypropyl)-5,9,9-trimethyl-6,7-benzomorphan hydrochloride Starting from the faster running substance (Rf 0.51) separated in Example 7, the title compound is obtained, 25 after conversion into the hydrochloride analogously to Example 2, in a yield of 2.2 g (64.7% of theory) with a *.4 melting point of 235'C (decomp.) and a specific rotation of -88.6-C (c 1, CHOH).
4.1.9 Example 9 (+)-(1S,5R,2"S)-2'-hydroxy-2-(2-methoxypropyl)-5,9,9-trimethyl-6,7-benzomorphan hydrochloride 2.60 g (0.025 mol) of (S)-2-methoxypropionic acid chloride are stirred in 100 ml of absolute tetrahydrofuran with 4.04 g (0.025 mol) of 1,1'- 29 carbonyldiimidazole for two hours at ambient temperature. After the addition of 4.62 g (0.020 mol) of (+)-2'-hydroxy-5,9,9-trimethyl-6,7-benzomorphan the mixture is stirred for a further two days at ambient temperature. It is then evaporated down, the residue is taken up in 75 ml of dichloromethane and washed successively with 2 N HC1 and twice with water. After separation the organic phase is dried with sodium sulphate and aft&k the drying agent has been filtered off, the residue is evaporated down in vacuo, finally at under a full water jet vacuum. The evaporation residue is reduced with lithium aluminium hydride (lithium tetrahydridoalanate) as described in Example 1 and the reaction product is crystallised as the hydrochloride analogously to Example 2. The title compound is obtained in a yield of 6.9 g (81.3% of theory) with a melting point of 264°C (decomp.) and a specific rotation of ]r5= +117.4° (c 1, CH 3
OH).
3t 4.1.10 Example (-)-(1R,5S,2"R)-9,9-dimethyl-5-ethyl-2'hydroxy-2-(2-methoxypropyl)-6,7-benzomorphan hydrochloride 25 Starting from 1.69 g (0.006 mol) of (±)-9,9-dimethyl-5ethyl-2'-hydroxy-6,7-benzomorphan hydrochloride [DOS 27 077; CA 74, 125482x (1971)], 1.82 g (0.018 mol) of S. triethylamine and 0.96 g (0.0078 mol) of methoxypropionic acid chloride, a mixture of the expected diastereomeric bases (1.7 g) is obtained analogously to Example 1, these bases being separated by column chromatography analogously to Example 2. The slower running substance (0.6 g, Rf 0.40) is crystallised out as the hydrochloride analogously to Example 2. The title compound is obtained in a yield of 0.6 g (56.6% of theory) with a melting point of 275"C (decomp.) and a specific rotation of [E]2 5 -100.5° 30 (c 1, CH 3
OH).
4.1.11 Example 11 (+)-(1S,5R,2"R)-9,9-dimethyl-5-ethyl-2'hydroxy-2-(2-methoxypropyl)-6,7-benzomorphan hydrochloride The faster running diastereomer (0.7 g, Rf 0.45) separated by column chromatography in Example 10 is crystallised out as the hydrochloride analogously to Example 2. The title compound is obtained in a yield of 0.23 g (21.7% of theory) with a melting point of 216"C (.decomp.) and a specific rotation of [a]2 5 +62.40 (c 1, CH 3
OH).
4.1.12 Example 12 S: (S,5R,2"S)-9,9-dimethyl-5-ethyl-2'hydroxy-2-(2-methoxypropyl)-6,7-benzomorphan hydrochloride Starting from 1.69 g (0.006 mol) of (±)-9,9-dimethyl-5ethyl-2'-hydroxy-6,7-benzomorphan hydrochloride, 1.82 g (0.018 mol) of triethylamine and 0..96 g (0.0078 mol) of (S)-2-methoxypropionic acid chloride, a mixture of the 25 expected diastereomeric bases (1.7 g) is obtained analogously to Example 1 and separated by column chromatography analogously to Example 2. The slower running substance (0.6 g, Rf 0.40) is crystallised out as the hydrochloride analogously to Example 2. The title compound is obtained in a yield of 0.6 g (56.6% of theory) with a melting point of 275"C (decomp.) and a specific rotation of [a] 2 5= +102.5° (c 1, CH 3
OH).
31 4.1.13 Example 13 (-)-(1R,5S,2"S)-9,9-dimethyl-5-ethyl-2'hydroxy-2-(2-methoxypropyl)-6,7-benzomorphan hydrochloride ThQ faster running diastereomer (0.6 g, Rf 0.45) separated by column chromatography according to Example 12 is crystallised out as the hydrochloride analogously to Example 2. The title compound is obtained in a yield 10 of 0.65 g (61.2% of theory) with a melting point of 219*C (decomp.) and a specific rotation of -67.6° (c 1, CHOH 4.1.14 Example 14 (-)-9,9-dimethyl-2'-hydroxy-2-((R)-2methoxypropyl)-5-phenyl-6,7-benzomorphan Starting from 1.7 ,g (6 mMol) of (t)-9,9-dimethyl-2'hydroxy-5-phenyl-6,7-benzomorphan [EP-B-4960; CA 93, 20 4941f (1980)] and 0.96 g (7.8 mMol) of O* methoxypropionic acid chloride, a mixture of the expected diastereomeric bases (2.1 g) is obtained analogously to Example 1 with Rf-values of 0.50 and 0.55 (cf. Example The mixture is crystallised out in the O 25 form of the hydrochloriCds (2.4 g) analogously to Example 2 and converted back into the corresponding free bases (evaporation residue 1.8 This base residue is recrystallised from 6 ml of ethyl acetate and 18 ml of petroleum ether (800C). Then the title compound is obtained in a yield of 0.72 g (65.5% of theory) with a melting point of 202°C, an Rf value of 0.50 and a specific rotation of [a]25= -24.4° (c 1, CH 3
OH).
32 4.1.15 Example (+)-9,9-dimethyl-2'-hydroxy-2-((R)-2-methoxypropyl)-5-phenyl-6,7-benzomorphan hydrochloride The mother liquor (ethyl acetate/petroleum ether) obtained during crystallisation according to Example 13 is evaporated down. The residue (1.2 g) is dissolved in ml of ethanol and the solution is acidified with 2.5 N 10 ethanolic hydrochloric acid. After the addition of diethylether until turbidity is beginning, hydrochloride (0.4 g) crystallises out as a contaminated crude product. The mother liquor contains the pure title compound which, after evaporation, is isolated as a residue: yield: 0.75 g (62.0% of theory), melting point 168 0 C (decomp.), Rf 0.55, specific rotation [z1 5 +11.6 1, CH 3 OH) 4.1.16 Example 16 20 (-)-(1R,5S,2"R)-3'-hydroxy-2-(2-methoxypropyl)-5,9,9-trimethyl-6,7-benzomorphan hydrochloride *to *o a) Starting compound The (±)-3'-hydroxy-5,9,9-trimethyl-6,7-benzomorphan required here and in other Examples is not known from the prior art. It may be prepared, for example, using the method of synthesis given for the known 2'-hydroxyisomer [DOS 20 27 077,; CA 74, (1971), 125482x], using m-methoxybenzyllithium instead of p-methoxybenzyllithium. When cyclisation is carried out to obtain the benzomorphan system, two isomeric compounds are obtained in the latter case which are further reacted in the form of a mixture. The mixture of l'-hydroxy- and 3'hydroxy-5,9,9-trimethyl-6,7-benzomorphan obtained finally is separated by flash column chromatography on 33 100 times the quantity of silica gel (MN K 60, 230-400 mesh ASTM, made by Macherey and Nagel) using a mixture of ethyl acetate/methanol/conc. ammonia 80:20:5 as eluant. The (±)-1'-hydroxy-5,9,9-trimethyl-6,7benzomorphan (Rf 0.20) and the (±)-3'-hydroxy-5,9,9trimethyl-6,7-benzomorphan (Rf 0.14) are obtained in a ratio of 1:2 in the form of viscous oils (Rf values: TLC, silica gel 60, using the eluant mentioned above).
10 b) Reaction to obtain the title compound *o i Starting from 2.31 g (0.010 mol) of (±)-3'-hydroxy- 5,9,9-trimethyl-6,7-benzomorphan and 1.6 g (0.013 mol) of (R)-2-methoxypropionic acid chloride, a mixture of the expected diastereomeric bases is obtained analogously to Example 1 which are separated by column chromatography on 100 times the quantity of silica gel analogously to Example 2. The slower running substance (Rf 0.65) is crystallised out as the hydrochloride, as 20 described therein. The title compound is obtained in a yield of 0.86 g with a melting point of 240 to 242"C (decomp.) and a specific rotation of [a]25= -90.9° (c 1, CHOH).
O 25 4.1.17 Example 17 (+)-(1S,5R,2"R)-3'-hydroxy-2-(2-methoxypropyl)-5,9,9-trimethyl-6,7-benzomorphan hydrochloride The faster running substance (Rf 0.74) separated in Example 16 is crystallised out as the hydrochloride analogously to Example 2. The title compound is obtained in a yield of 1.28 g (75.3% of theory) with a melting point of 250-251'C and a specific rotation of [aD +57.1° (c 1, CH OH).
34 4.1.18 Example 18 (+)-(1S,5R,2"S)-3'-hydroxy-2-(2-methoxypropyl)-5,9,9-trimethyl-6,7-benzomorphan hydrochloride Starting from 2.31 g (0.010 mol) of (±)-3'-hydroxy- 5,9,9-trimethyl-6,7-benzomorphan (see Example 16) and 1.60 g (0.013 mol) of (S)-2-methoxypropionic acid chloride, a mixture of the expected diastereomeric bases 10 is obtained analogously to Example 1, which are purified by chromatography analogously to Example 2 on 100 times the amount of silica gel. The slower running substance 0.65) is crystallised as the hydrochloride as described therein. The title compound is obtained in a yield of 0.57 g (33.4% of theory) with a melting point of 239 to 240°C (decomp.) and a specific rotation of [a] 25 +90.7° (c 1, CHOH) 4.1.19 Example 19 20 (-)-(lR,5S,2"S)-3'-hydroxy-2-(2-methoxypropyl)-5,9,9-trimethyl-6,7-benzomorphan hydrochloride The faster running substance (Rf 0.74) separated in 25 Example 18 is crystallised out as the hydrochloride analogously to Example 2. The title compound is obtained in a yield of 0.67 g (39.2% of theory) with a melting point of 250-251°C (decomp.) and a specific rotation of -56.5* (c 1, CH 3
OH).
4.1.20 Example (-)-(1R,5R,2"R)-1'-hydroxy-2-(2-methoxypropyl)-5,9,9-trimethyl-6,7-benzomorphan hydrochloride Starting from 2.31 g (0.010 mol) of (±)-l'-hydroxy- 5,9,9-trimethyl-6,7-benzomorphan (see Example 16) and 35 1.60 g of (R)-2-methoxypropionic acid chloride, a mixture of the expected diastereomeric bases is obtained analogously to Example 1 which are separated analogously to Example 2 on 100 times the amount of silica gel. The slower running substance (Rf 0.52) is crystallised as the hydrochloride analogously to Example 2. The title compound is obtained in a yield of 0.70 g (41.2% of theory) with a melting point of 128-135*C (decomp.) and a specific rotation of [a] 25 -100.5" (c 1, CH 3
OH).
4.1.21 Example 21 (+)-(lS,5S,2"R)-l'-hydroxy-2-(2-methoxypropyl)-5,9,9-trimethyl-6,7-benzomorphan hydrochloride The faster running substance (Rf 0.56) separated off in Example 20 is crystallised as the hydrochloride analogously to Example 2. The title compound is obtained in a yield of 0.40 g (23.6% of theory) with a 20 melting point of 88 to 89"C (decomp.) and a specific rotation of [a]D5= 50.4° (c 1, CH 3
OH).
4.1.22 Example 22 -hydroxy-2-(2-methoxypropyl)-5,9,9-trimethyl-6,7-benzomorphan hydrochloride Starting from 2.31 g (0.010 mol) of (±)-l'-hydroxy- 5,9,9-trimethyl-6,7-benzomorphan (see Example 16) and 1.60 g (0.013 mol) of (S)-2-methoxy-propionic acid chloride a mixture of the expected diastereomeric bases is obtained analogously to Example 1 which are separated on 100 times the amount of silica gel in accordance with Example 2. The slower running substance (Rf 0.52) is crystallised out as the hydrochloride analogously to Example 2. The title compound is obtained in a yield of 0.63 g (36.8% of theory) with a melting point of 85 to 36 and a specific rotation of [a]2 5 +96.2* (c 1,
CH
3
OH).
4.1.23 Example 23 (-)-(1R,5R,2"S)-1'-hydroxy-2-(2-methoxypropyl)-5,9,9-trimethyl-6,7-benzomorphan hydrochloride "-Thfe faster running substance (Rf 0.56) separated in 10 Example 22 is crystallised as the hydrochloride analogously to Example 2. The title compound is i9 ;obtained in a yield of 0.50 g (29.4% of theory) with a melting point of 90 to 91"C (decomp.) and a specific rotation of -64.0* (c 1, CH3OH).
4.1.24 Example 24 (-)-(1R,5S,2"R)-4'-hydroxy-2-(2-methoxypropyl)-5,9,9-trimethyl-6,7-benzomorphan hydrochloride 9 a) Preparation of the starting compound The preparation of (±)-4'-hydroxy-5,9,9-trimethyl-6,7benzomorphan needed here and in other Examples is not O 25 known from the prior art. It may, for example, be prepared by the method of synthesis known from the prior art for the known 2'-hydroxy-isomer [DOS 20 27 077, CA 74, 125482x (1971)] by using o-methoxybenzyllithium instead of p-methoxybenzyllithium. The desired compound crystallises as a base from isopropanol-petroleum ether with a melting point of 227 0 C. In thin layer chromatography (silica gel 60, chloroform/methanol/conc.
ammonia 65:35:3) it may be given an Rf value of 0.20.
b) Reaction to obtain the title compound Starting from 2.31 g (0.010 mol) of (±)-4'-hydroxy- 37 5,9,9-trimethyl-6,7-benzomorphan and 1.60 g (0.01 mol) of (R)-2-methoxypropionic acid chloride, a mixture of the expected bases (3.0 g) is obtined analogously to Example 1, which are separated analogously to Example 2 by column chromatography on 450 g of silica gel. 0.9 g of the slower running compound (Rf 0.34) and 1.3 g of the faster running compound (Rf 0.43) are obtained.
The former is crystallised as the hydrochloride as in Example 2. The title compound is thus obtained in a 10 yield of 0.95 g (55.9% of theory) with a melting point of 263"C (decomp.) and the specific rotation of [a] 2 -86.9 (c CHOH) 4.1.25 Example (+)-(lS,5R,2"R)-4'-hydroxy-2-(2-methoxypropyl)-5,9,9-trimethyl-6, 7-benzomorphan l hydrochloride The faster running compound (Rf 0.43) separated in 20 Example 24 is crystallised as the hydrochloride analogously to Example 2. The title compound is obtained in a yield of 1.23 g (72.4% of theory) with a melting point of 258"C (decomp.) and a specific rotation of +51.70, (c 1, CH 3
OH).
4.1.26 Example 26 (+)-(lS,5R,2"S)-4'-hydroxy-2-(2-methoxypropyl)-5,9,9-trimethyl-6,7-benzomorphan hydrochloride Starting from 2.31 g (0.010 mol) of (±)-4'-hydroxy- 5,9,9-trimethyl-6,7-benzomorphan (see Example 24) and 1.60 g (0.013 mol) of (S)-2-methoxypropionic acid chloride, a mixture of the expected diastereomeric bases (3.1 g) is obtained which are separated by column chromatography on 450 g of silica gel analogously to Example 2. 1.0 g of the slower running compound (Rf 38 0.34) and 1.2 g of the faster running compound are obtained. The former is crystallised in the form of the hydrochloride analogously to Example 2 and yields the title compound in a yield of 1.15 g with a melting point of 260C (decomp.) and a specific rotation of [a]2 5 -51.2° (c 1, CHOH) 4.1.27 Example 27 (-)-(1R,5S,2"S)-4'-hydroxy-2-(2-methoxy- 10 propyl)-5,9,9-trimethyl-6,7-benzomorphan hydrochloride The faster running substance (Rf 0.43) separated in Example 26 is crystallised as the hydrochloride analogously to Example 2 and yields the title compound in a yield of 0.95 g (55.9% of theory) with a melting point of 261 0 C (decomp.) and a specific rotation of a] (c 1, S 20 4.1.28 Example 28 (-)-(lR,5S,2"R)-2'-methoxy-2-(2-methoxypropyl)-599,9-trimethyl-6,7-benzomorphan methanesulphonate Starting from 2.45 g (0.010 mol) of (-)-2'-methoxy- 5,9,9-trimethyl-6,7-benzomorphan [DOS 20 27 077; CA 125482x (1971)] and 1.35 g (0.011 mol) of (R)-2-methoxypropionic acid chloride, the sterically uniform title compound is obtained analogously to Example 1 in the form of the free base (2.3 This is dissolved in ml of absolute ethanol. After acidification with methanesulphonic acid the solution obtained is combined with diethylether until turbidity is just beginning.
Whilst the methanesulphonate is crystallising, the same amount of ether is gradually added once more with stirring. Then the reaction mixture is cooled for 4 hours with an ice bath, suction filtered, then washed 39 first with a 1:2 mixture of ethanol and ether and then with ether on its own. After drying, finally at the title compound is obtained in a yield of 3.3 g (79.8% of theory) with a melting point of 165-166°C (decomp.) and a specific rotation of [a] 2 5= -92.4" (c 1, CH 3 0H).
4.1.29 Example 29 (+)-(lS,5R,2"S)-2'-methoxy-2-(2-methoxy- 10 propyl)-5,9,9-trimethyl-6,7-benzomorphan b* methanesulphonate Starting from 2.45 g (0.010 mol) of (+)-2'-methoxy- 5,9,9-trimethyl-6,7-benzomorphan [DOS 20 27 077; CA 74, 125482x (1971)] and 1.35 g (0.011 mol) of methoxypropionic acid chloride, the title compound is obtained analogously to Example 28 in a yield of 3.1 g (75.0% of theory) with a melting point of 165-167°C (decomp.) and a specific rotation of +92.3° 20 (c 1, CH3H) 4.1.30 Example (-)-(lR,5S,2"R)-2-(2-methoxypropyl)-5,9,9trimethyl-6,7-benzomorphan hydrochloride O a) Preparation of the starting compound The preparation of (±)-5,9,9-trimethyl-6,7-benzomorphan required here and in other Examples is not known from the prior art. It may be prepared, for example, using the method of synthesis given for the known 2'-hydroxy derivative [DOS 20 27 077; CA 74 (1971) 125482x], using benzyllithium instead of p-methoxybenzyllithium. The desired compound crystallises as a hydrobromide from an isopropanol-ether mixture with a melting point of 259"C (decomposition).
40 b) Reaction to obtain the title compound Starting from 2.96 g (0.010 mol) of (±)-5,9,9-trimethyl- 6,7-benzomorphan and 1.35 g (0.011 mol) of methoxypropionic acid chloride, a mixture of the expected diastereomeric bases is obtained analogously to Example 1. These are separated according to Example 2 by column chromatography on 150 times the amount of silica gel. The slower running substance (Rf 0.63) is T 10 crystallised as the hydrochloride, as described therein.
The title compound is obtained in a yield of 1.3 g (76.5% of theory) with a melting point of 225°C (decomp.) and a specific rotation of -101.7° (c 1, Ch3OH).
4.1.31 Example 31 (+)-(lS,5R,2"R)-2-(2-methoxypropyl)-5,9,9trimethyl-6,7-benzomorphan oxalate 20 The faster running substance (Rf 0.67) separated in Example 30 is dissolved with 5 ml of ethanol. After acidification with oxalic acid the solution is mixed with diethylether until turbidity is just beginning.
'During the crystallisation which then sets in, half the original quantity of ether is gradually added and the mixture is left in the refrigerator for about 12 hours.
After suction filtering, washing with an ethanol-ether mixture and drying at 80°C, the title compound is obtained in a yield of 1.1 g (60.4% of theory) with a melting point of 135"C (decomp.) and a specific rotation of +60.2° (c 1, CH 3 OH) 4.1.32 Example 32 (-)-(1R,5S,2"R)-2-(2-Methoxypropyl)-2',5,9,9tetramethyl-6,7-benzomorphan hydrochloride a) Preparation of the starting compound 41 The (±)-2'-5,9,9-tetramethyl-6,7-benzomorphan required here and in other Examples is not known from the prior art. It may, for example, be prepared using the method of synthesis given for the known 2'-hydroxy-analogue, using p-methylbenzyllithium instead of pmethoxybenzyllithium. The intermediate product thus obtained is crystallised in the form of the hydrobromide from an isopropyl-diethylether mixture and melts at 227"C with decomposition.
b) Reaction to obtain the title compound Starting from 1.51 g (5 mMol) of tetramethyl-6,7-benzomorphan and 0.68 g (5.5 mMol) of (R)-2-methoxypropionic acid chloride, a mixture of the expected diastereomeric bases is obtained analogously to Example 1, which are crystallised as the hydrochlorides and separated as described therein. The title compound i is obtained in a yield of 0.7 g (after recrystallisation 0.4 g 47.3% of theory) with a melting point of 212°C (decomp.) and a specific rotation of [c]n 25 -110.0° (c 1, CH 3
OH).
4.1.33 E\,ample 33 (+}-lS,5R,2"S)-2-(2-methoxypropyl)-2'-5,9,9trimethyl-6,7-benzomorphan hydrochloride Starting from 1.5' g (5 mMol) of tetramethyl-6,7-benzomorphan and 0.68 g (5.5 mMol) of (S)-2-methoxypropionic acid chloride the title compound is obtained analogously to Example 32 in a yield of 0.4 g (47.3% of theory) with a melting point of 212°C (decomp.) and a specific rotation of [D] 5 +111.8° (c 1, CHOH).
42 I 4.1.34 Example 34 (-)-(1R,5S,2"R)-2'-amino-2-(2-methoxypropyl)- 5,9,9-trimethyl-6,7-benzomorphan dihydrochloride a) Preparation of the starting compound The (±)-2'-nitro-5,9,9-trimethyl-6,7-benzomorphan required here and in other Examples is not known from the prior art. It can be prepared for example by *nitrogenation of the (±)-5,9,9-trimethyl-6,7benzomorphan (Example 30) analogously to a method described by E.L. May and E.M. Fry Org. Chem. 22 (1957) 1366]. The resulting intermediate compound is crystallised from an ethanol-ether mixture as the hydrochloride, melting at 289*C (decomp.).
b) Acylation 2.97 g (0.01 mol) of (±)-2'-nitro-5,9,9-trimethyl-6,7benzomorphan hydrochloride are acylated in the presence of 3.04 g (0.03 mol) of triethylamine analogously to Example 1 with 1.35 g (0.011 mol) of methoxypropionic acid chloride. After working up, 3.5 g O 25 (about 100% of theory) of the intermediate product of type are obtained.
c) Catalytic hydrogenation of the 2'-nitro- to the 2'amino- group g of the intermediate product resulting from step b) are dissolved in 70 ml of methanol and hydrogenated in the presence of 0.4 g of palladium on charcoal (Pd content: at 20 0 C under a hydrogen pressure of 5 bar.
The uptake of hydrogen ceases after 4 hours, after the calculated amount has been consumed. After the catalyst has been filtered off the reaction mixture is evaporated 43 down, finally at 80°C under a total water jet vacuum.
Residue: 3.1 g (about 100% of theory).
d) Reduction with lithium aluminium hydride The evaporation residue (3.1 g) obtained above is reduced analogously to Example 1 with 1.3 g of lithium aluminium hydride (lithium tetrahydridoalanate). The resulting mixture of the two expected diastereomeric 10 bases (2.7 g) is separated analogously to Example 2 by column chromatography on 500 g of silica gel. The slower running substance (0.7 g, Rf 0.65) is crystallised as the dihydrochloride analogously to Example 2 (but with two equivalents of hydrochloric acid). The title compound is obtained in a yield of 0.95 g (50.6% of theory) and with a melting point of 260'C (decomp.) and a specific rotation of [a] 25 -93.4° (c 1, Ik 20 4.1.35 Example sot '(+)-(lS,5R,2"R)-2'-amino-2-(2-methoxypropyl)fe 5,9,9-trimethyl-6,7-benzomorphan dimethanesulphonate 0.9 g of the faster running substance (Rf 0.70) separated in Example 34 are crystallised from a mixture of methanol and diethylether analogously to Example 28 (but with 2 equivalents of methanesulphonic acid). The title compound is obtained in a yield of 0.48 g (19.4% of theory) with a melting point of 189*C (decomp.) and a specific rotation of [a]2 5 +55.6° (c 1, CH 3
OH).
4.1.36 Example 36 (+)-(1S,5R,2"S)-2'-amino-2-(2-methoxypropyl)- 5,9,9-trimethyl-6,7-benzomorphan hydrochloride Starting from 2.97 g (0.01 mol) of 5,9,9- 44 trimethyl-6,7-benzomorphan hydrochloride, 3.04 g (0.03 mol) of triethylamine and 1.35 g (0.011 mol) of (S)-2-methoxypropionic acid chloride, 3.5 g (around 100% of theory) of the acylation product are obtained which, as described therein, is catalytically hydrogenated (producing 3.2 g of hydrogenation product) and then reduced with lithium aluminium hydride (lithium tetrahydroalanate). The reduction product (2.8 g), consisting of a mixture of the expected diastereomeric 10 bases, is dissolved in 10 ml of isopropanol with heating. Over a period of about 12 hours, as the mixture is left to stand in the refrigerator, the substance which is slower running in chromatography S(Rf 0.65) crystallises as a base (0.75 g 49.0% of theory) with a melting point of 142*C. Of this, 0.3 g were crystallised as the dihydrochloride analogously to Example 32. The title compound (0.37 g) is obtained with a melting point of 265 0 C (decomp.) and a specific rotation of [a] 5 +92.5° (c 1, CH 3
OH).
4.1.37 Example 37 (-)-(1R,5S,2"S)-2'-amino-2-(2-methoxy-propyl)- 5,9,9-trimethyl-6,7-benzomorphan S* dihydrochloride O The isopropanol mother liquor of Example 34 is evaporated down and the residue (2.0 g) is chromatographed on 300 g of silica gel analogously to Example 2. The faster running diastereomer (1.2 g, Rf 0.70) together with another 0.3 g of the slower running substance (Rf 0.65, Example 34) is crystallised as the dihydrochloride analogously to Example 32. The title compound is obtained in a yield of 1.48 g (78.8% of theory) with a melting point of 259'C (decomp.) and a specific rotation of (o]25= -68.4' (c 1, Cft 3
H).
45 (±)-2'-hydroxy-2-(2-methoxyisobutyl)-5,9,9trimethyl-6,7-benzomorphan hydrobromide Starting from 1.16 g (0.005 mol) of oxy- 5,9,9-trimethyl-6,7-benzomorphan and 0.75 (0.055 mol) of 2-methoxyisobutyric acid chloride, rst the base form of the title compound (1.1 g) sobtained analogously to Example 1. This s dissolved in 5 ml of 10 methanol and after acidific on with HBr the S• solution is mixed with d' hylether until turbidity is just setting in. Whe left to stand for about 12 hows, in the refrigerat the title compound crystallises out, is suction fil red, washed with a mixture of ethanol and ether dried at 80*C. Yield 1.1 g (55.2% of theory) melting point 2320C (decomp.). A sample recr tallised from methanol-ether mixture melts at 61 20 4.1.39 Example 39 (-)-(lR,5S,2"R)-2'-hydroxy-2-(2-methoxybutyl)- 5,9,9-trimethyl-6,7-benzomorphan hydrochloride a) Preparation of the starting compound The (R)-2-methoxy-butyric acid chloride needed in this and other Examples may, for example, be prepared from the known (R)-2-methoxybutyric acid Kochetkov, A.M. Likhosherstov and V.N. Kulakov, Tetrahedron (1969) 2313] and thionylchloride at ambient temperature.
The acid chloride remaining after the excess thionylchloride has been removed is used in the next reaction step without any further purification.
Reaction to obtain the title compound Starting from 3.47 g (0.015 mol) of (±)-2'-hydroxy- 1t I*r, 46 5,9,9-trimethyl-6,7-benzomorphan and 2.46 g (0.018 mol) of (R)-2-methoxybutyric acid chloride the title compound is obtained analogously to Example 1 in a yield of 1.8 g (67.8% of theory) with a melting point of 246*C (decomp.) and a specific rotation of [a121 -118.4- (c CH 3
OH).
4.1..40 Example W -(1S5 R,2"R) -2 '-hydroxy-2- (2-methoxybutyl) 5,9, 9-trimethyl-6, 7-benzomorpha',n hydrochloride a 0* does 6* a The mother liquor obtained in Example 39 is evaporated down. From the residue, the title cmpound is obtained analogously to Example 2 in a yield of 1.3 g (48.9% of 15 theory) with a melting point of 228*C (decomp.) and a specific rotation of +79.9- (c 1, CH OH) 4.1.41 Example 4; 5S, 2"S) -2 '-hydroxy-2- (2-methoxybutyl) 5,9, 9-trimethyl-6, 7-benzomorphan hydrochloride a) Preparation of the starting compound The (S)-2-methoxybutyric acid chloride needed in this 0 25 and in other Examples may for example be prepared from the known (S)-2-methoxy-butyric acid [Tetrahedron (1969) 2322] analogously to Example 39.
b) Reaction tl~ the title compound Starting from 3.47,,rg (0.015 mol) of (±)-2'-hydroxy- 5,9,9-trimnethyl-6,7-benzomorph 'an and 2.46 g (0.018 Inol) of (S)-2-methoxybutyric acid chloride, the title compound is obtained analogously to Example 1 in a yield of 1.6 g (60.3% of theory) with a melting point of 246*C (decomp.) and a specific rotation of (a2=+119.2- II(c 1, CH OH) 4;)Q 3 47 4.1.42 Example 4a (+)-(iS,5R,2"S)-2'-hydroxy-2-(2-methoxybutyl)- 5,9,9-trimethyl-6,7-benzomorphan hydrochloride The tmother liquor obtained in Example 41 is evaporated down. From the residue, the title compound is obtained analogously to Example 2 in a yield of 0.6 g (22.6% of theory) with a melting point of 228 0 C (decomp.) and a specific rotation of [a] 5 -71.7° (c 1, CHOH).
4.1.43 Example 49: ~(-)-(iR,5S,2"R)-2-(2-benzyloxypropyl)-2'- S...hydroxy-5,9,9-trimethyl-6,7-benzomorphan hydrochloride a) Preparation of the starting compound The (R)-2-benzyloxypropionic acid chloride used here and in other Examples may for example be prepared as 20 follows: Commercial isobutyl (R)-(+)-lactate is O-benzylated with benzylbromide in the presence of silver oxide. The subsequent saponification with sodium hydroxide solution yields (R)-2-benzyloxy-propionic acid with a specific rotation of +79.5" (c 1, CH 3 OH). The correjsponding acid chloride is obtained from this analogously to Example 39.
b) Reaction to the title compound Starting from 3.47 g (0.015 mol) of (±)-2'-hydroxy- 5,9,9-trimethyl-6,7-benzomorphan and 3.3 g (0.0165 mol) of (R)-2-benzyloxypropionic acid chloride, a mixture of the expected diastereomers is obtained analogously to Example 1, which are separated by crystallisation of the corresponding hydrochlorides as described in that S Example. The title compound is obtained in a yield of 48 2.39 g (76.6% of theory) with a melting point of 250*C (decomp.) and a specific rotation of [(a]2 5 119.39 (c 1, CH 1 3 1IH).
4.1.44 Example *4 (+)-(lS,5R,2"S)-2-(2-benzyloxypropyl)-2'- 9, 9-trimethyl-6, 7-benzomorphan hydrochloride 9.
10 a) Preparation of the starting compound The (S)-2-benzyloxypropionic acid chloride used here and in other Examples may for example be prepared analogously to Example 43 from (S)-2-benzyloxypropionic acid (specifi~c rotation: (a]25= -7 8.5 (c 1, CH OH)) D. 3 b) Reaction to the title compound **'*Starting from 3.47 g (0,015 mol) of (±)-2'-hydroxy- 20 5,9,9-trimethyl-6,7-benzomorphan and 3.3 g (0.0165 mol) of (S)-2-benzyloxypropionic acid chloride the title vcowpound is obtfained analIogously to Example 43 in a yield of 2.56 g o8.f6-f theory) with a melting point of 250*C (decomp.) and a specific rotation of [ax325 +119.5 0(c 1, CH 3 OH) 4.1.45 Example -(lR,5S, 2"R) -2 '-hydroxy-2-(2-methylthiiopropyl) 9-trimethyl-6, 7-benzomorph(An hydrochloride a) Preparation of the starting compound The (R)-2-methylthiopropionic acid chloride required here and in other Examples may for example be prepared analogously to Example 39 from the known methylthio-propionic -acid Owen and M.B. Rahman J.
49
S.
S
O
6 S. 6 q
S.S
5 S.
S
*55e
S
6056 0**6
S
*5 S.6 Chem. Soc. 1971, 2432].
b) Reaction to the title compound 1.62 g (0.007 mol) of (±)-2'-hydroxy-5,9,9-trimethyl- 6,7-benzomorphan are reacted analogously to Example 1 with 1.07 g (7.7 mMol) of (R)-2-methylthio-propionic acid chloride. After reduction of the reaction product with lithium aluminium hydride (LiAlH 4 a mixture of the 10 expected diastereomers is obtained, which are separated by crystallisation of their nitrates. The substance which crystallises from ethanol after acidification with nitric acid and the addition of diethylether until turbidity sets in is left to stand in the refrigerator 15 for about 12 hours, then suction filtered, washed with a mixture of ethanol and ether and then with ether and dried at 80*C. The nitrite (0,67 g) is recrystallised from boiling ethanol (0.52 then converted into the free base and finally crystallised as the hydrochloride 20 analogously to Example 2. The title compound is obtained in a yield of 0.43 g (34.4% of theory) with a melting point of 265°C (decomp.) and a specific rotation of -135.1° (c 0.5 CH 3
OH).
4.1.46 Example YK (+)-(lS,5R,2"R)-2'-hydroxy-2-(2-methylthiopropyl)-5,9,9-trimethyl-6,7-benzomorphan hydrochloride The mother liquor of the first nitrate crystallisation obtained according to Example 45 is evaporated down and the nitrate residue is converted into the free base.
This (1 g) is filtered over 20 g of aluminium oxide as 64 in Example SS and then crystallised as the hydrochloride (ethanol/ether). This hydrochloride (0.29 g) is recrystallised from a mixture of 2 ml of methanol and diethylether. The title compound is obtained in a yield 54:i L 50 of 0.21 g (16.8% of theory) with a melting point of 238 0 C (decomp.) and a specific rotation of [a] 5 +73.0° (c 0.5, 4.1.47 Example W (-)-(lR,5S,2"S)-2'-hydroxy-2-(2-methylthiopropyl-5,9,9-trimethyl-6,7-benzomorphan hydrochloride 1 0 a) Preparation of the starting compound .3 The (S)-2-methylthiopropionic acid chloride needed here and in other Examples may be prepared for example from the known (S)-2-methylthiopropionic acid Chem. Soc.
1971, 2437] analogously to Example 3J9.
b) Reaction to the title compound S Starting from 1.62 g (0.007 mol) of (±)-2'-hydroxy- 20 5,9,9-trimethyl-6,7-benzomorphan, the title compound is obtained analogously to Example 45 in a yield of 0.42 g (33.6% of theory) with a melting point of 265*C (decomp.) and a specific rotation of +135.1' (c CH 3
OH).
4.1.48 Example (-)-(lR,5S,2"S)-2'-hydroxy-2-(2-methylthiopropyl-5,9,9-trimethyl-6 7-benzomorphan hydrochloride Starting from the nitrate mother liquor in Example 47, the title compound is obtained analogously to Example 46 in a yield of 0.34 g (27.2% of theory) with a melting point of 2386C (decomp.) and a specific rotation of -73.9" (c 0.5, CH 3
OH).
51 4.1.49 Example 4M (+)-(lS,5R,2"S)-2-(2-allyloxypropyl)-2'hydroxy-5,9,9-trimethyl-6,7-benzomorphan hydrochloride a) Preparation of the starting compound The (S)-(-)-2-allyloxy-propionic acid chloride used here Smay be prepared as follows, for example: commercial ethyl (S)-(-)-lactate is o-allylated with allylbromide in the presence of silver oxide. Subsequent saponification with sodium hydroxide solution yields (S)-2-allyloxy-propionic acid with a boiling point of 110 to 112°C at a pressure of 15 mbar and a specific rotation of [a]2 5 78.4° (c 1, CHO3H). The corresponding acid chloride is obtained therefrom analogously to Example 39.
b) Reaction to the title compound Starting from 3.47 g (0.015 mol) of (±)-2'-hydroxy- 5,9,9-trimethyl-6,7-benzomorplian and 3.3 g (0.0165 mol) of (S)-2-allyloxy-propionic acid chloride, a mixture of the two expected diastereomers is obtained analogously 25 to Example 1, which is separated as described therein by crystallisation of the corresponding hydrochlorides.
The title compound is obtained in a yield of 1.4 g (51.0% of theory) with a melting point of 245°C (decomp.) and a specific rotation of [a] 5 +120° (c 1,
CHOH).
149 4.1.50 Example O R,2"S)-2-(2-allyloxypropyl)-2 hydroxy-5,9,9-trimethyl-6,7-benzomiorphan hydrochloride The fmother liquors obtained in Example 49 are evaporated iTj 52 down. From the residue, the title compound is obtained analogously to Example 2 in a yield of 0.62 g (22.6% of theory) with a melting point of 213*C and a specific rotation of [a]25= -38.6° (c 1, 4.1.51 Example S1 (-)-(1R,5S,2"R)-2'-hydroxy-2-(2-phenoxypropyl)-5,9,9-trimethyl-6,7-benzomorphan hydrochloride 2.31 g (0.010 mol) of (±)-2'-hydroxy-5,9,9-trimethyl- O 6,7-benzomorphan and 2.03 g (0.011 mol) of phenoxypropionic acid chloride (prepared analogously to Example 39 from the known acid [CA 72, 12917d]) are reacted analogously to Example 1. A mixture of the two expected diastereomers is obtained which, as described therein, is separated by crystallisation of the corresponding hydrochlorides. In this way, the title compound is obtained in a yield of 1.6 g (79.6% of S 20 theory) with a melting point of 279*C (decomp.) and a specific rotation of 5 -142.9* (c 1, CH 3
OH).
51 4.1.52 Example l (+)-(IS,5R,2"S)-2'-hydroxy-2-(2phenoxypropyl)-5,9,9-trimethyl-6,7benzomorphan hydrochloride By proceeding as in Example 1 with (S)-2-phenoxypropionic acid chloride the title compound is obtained in a yield of 1.6 g with a specific rotation of 5 +143.3°C (c CH 3
OH).
x\ x ;i 1 53 4.1.53 Example 59, (-)-(1R,5S,2"R)-3'-hydroxy-2-(2-methoxypropyl)-5,9,9,2'-tetramethyl-6,7-benzomorphan hydrochloride a) Starting compound The (+/-)-3'-hydroxy-5,9,9,2'-tetramethyl-6,7benzomorphan required here and in other Examples is not known from the prior art. It may be prepared, for example, using the method of synthesis given for the known 2'-hydroxy derivative [DOS 20 27 077; CA 74 (1971), 125482x] using 3-methoxy-4-methylbenzyllithium instead of p-methoxybenzyllithium. The 3'-hydroxy- 5,9,9,2'-tetramethyl--6,7-benzomorphan which is predominantly obtained on cyclisation to the benzomorphan system is purified by flash column chromatography (cf. Example 16).
S 20 b) Reaction to the title compound Starting from 2.44 g (0.010 mol) of (+/-)-3'-hydroxy- 5,9,9,2'-ttmeramethyl-6,7-benzomorphan and 1.6 g (0.013 mol) of (R)-2-methoxypropionic acid chloride a .4 25 mixture of the expected diastereomeric bases is obtained analogously to Example 1 which are separated by column chromatography on 100 times the quantity of silica gel, analogously to Example 2. The slower running substance (Rf 0.25) is crystallised out as the hydrochloride.
The title compound is obtained in a yield of 1.06 g with a melting point of 181-182°C and a specific rotation of [a]25= -89.5 (c 1, CH 3
OH).
54 53 4.1.54 Example (+)-(IS,5R,2"R)-3'-hydroxy-2-(2-methoxypropyl)-5,9,9,2'-tetramethyl-6,7-benzomorphan hydrochloride The faster running substance (Rf 0.34) separated off in Example 53 is precipitated as the hydrochloride analogously to Example 2. The title compound is obtained in a yield of 1.24 g as an amorphous powder with a specific rotation of [a]1 5 +55.9° (c 1,
CH
3
OH).
4.1.55 Example (+)-(1',5R,2"S)-3'-hydroxy-2-(2-methoxypropyl)-5,9,9,2'-tetramethyl-6,7-benzomorphan hydrochloride Starting from 2.44 g (0.010 mol) of (+/-)-3'-hydroxy- 5,9,9,2'-tetramethyl-6,7-benzomorphan (see Example 53) S 20 and 1.6 g (0.013 mol) of (S)-2-methoxy-propionic acid chloride a mixture of the expected diastereomeric bases o is obtained analogously to Example 1 which are separated by column chromatography on 100 times the quantity of silica gel analogously to Example 2. The slower running 25 substance (Rf 0.25) is crystallised out in the form of the hydrochloride. The title compound is obtained in a yield of 1.48 g with a melting point of 186-188*C and a specific rotation of +88.2' (c 1, CHOH).
4.1.56 Example (-)-(1R,5S,2"S)-3'-hydroxy-2-(2methoxypropyl)-5,9,9,2'-tetramethyl-6,7benzomorphan hydrochloride The faster running substance (Rf 0.34) separated off in Example 55 is precipitated as the hydrochloride 55 analogously to Example 2. The title compound is obtained in a yield of 1.40 g as an amorphous powder with a specific rotation of 5 -56.8" (c 1,
CH
3
OH).
4.1.57 Example (-)-(1R,5S,2"R)-2'-hydroxy-2-(2-methoxypropyl)- 5,9,9,3'-tetramethyl-6,7-benzomorphan methanesulphonate a) Starting compound The (+/-)-2'-hydroxy-5,9,9,3'-tetramethyl-6,7be;zomorphan required here and in other Examples is not known from the prior art. It may, for example, be prepared by the method of synthesis given for the known 2'-hydroxy derivative [DOS 20 27 077; CA 74 (1971), 125482x], using 4-methoxy-3-methylbenzyllithium instead S of p-methoxybenzyllithium. The 2'-hydroxy-5,9,9,3'- 20 tetramethyl-6,7-benzomorphan which is predominantly obtained on cyclisation to form the benzomorphan system Sis purified by flash column chromatography (cf. Example 16).
25 b) Reaction to obtain the title compound Starting from 2.44 g (0.010 mol) of (+/-)-2'-hydroxy- 5,9,9,3'-tetramethyl-6,7-benzomorphan and 1.6 g (0.013 mol) of (R)-2-methoxypropionic acid chloride a mixture of the expected diastereomeric bases is obtained analogously to Example 1, which is separated by column chromatography on 100 times the quantity of silica gel analogously to Example 2. The slower running substance (Rf 0.26) is crystallised out as the methanesulphonate.
The title compound is obtained in a yield of 1.64 g with a melting point of 266-268°C and a specific rotation of [a]25= -95.4° CH 3
OH).
56 57 4.1.58 Example W (+)-(iS,5R,2"R)-2'-hydroxy-2-(2-methoxypropyl)-5,9,9,3'-tetramethyl-6,7-benzomorphan hydrochloride The faster running substance (Rf 0.29) separated off in Example 57 is precipitated as the hydrochloride analogously to Example 2. The title compound is obtained in a yield of 1.60 g as an amorphous powder with a specific rotation of +73.4° (c 1,
CHOH).
4.1.59 Example Se (+)-(1S,5R,2"S)-2'-hydroxy-2-(2-methoxypropyl)-5,9,9,3'-tetramethyl-6,7-benzomorphan methanesulphonate Starting from 2.44 g (0.010 mol) of (+/-)-2'-hydroxy- 5,9,9,3'-tetramethyl-6,7-benzomorphan (see Example 57) and 1.6 g (0i.013 mol) of (S)-2-methoxy-propionic acid chloride, a mixture of the expected diastereomeric bases is obtained analogously to Example 1, which is separated by column chromatography on 100 times the amount of silica gel analogously to Example 2. The slower running 25 substance (Rf 0.26) is crystallised out as the methanesulphonate. The title compound is obtained in a yield of 1.56 g with a melting point of 265-267'C and a specific rotation of +96.9' (c 1, CH OH).
4.1.60 Example WD (-)-(1R,5S,2"S)-2'-hydroxy-2-(2-methoxypropyl)-5,9,9,3'-tetramethyl-6,7-benzomorphan hydrochloride The faster running substance (Rf 0.29) separated in Example 59 is precipitated as the hydrochloride 57 analogously to Example 2. The title compound is obtained in a yield of 1.36 g as an amorphous powder with a specific rotation of [c] 5 -74.9" (c 1,
CH
3
OH).
4.1.61 Example 14 (-)-(1R,5S,2"R)-2',3'-dihydroxy-2-(2-methoxypropyl)-5,9,9-trimethyl-6,7-benzomorphan hydrochloride a) Starting compound The (+/-)-2',3'-dihydroxy-5,9,9-trimethyl-6,7benzomorphan required here and in other Examples is not S 15 known from the prior art. It may, for example, be prepared by the method of synthesis given for the known 0* 2'-hydroxy derivative [DOS 20 27 077; CA 74 (1971), 125482x], using 3,4-dimethoxybenzyllithium instead of pmethoxybenzyllithium. The 2',3'-dihydroxy-5,9,9trimethyl-6,7-benzomorphan predominantly obtained on cyclisation to form the benzomorphan system is purified by flash column chromatography (cf. Example 16).
0 b) Reaction to form the title compound Starting from 8.51 g (0.03 mol) of dihydroxy-5,9,9-trimethyl-6,7-benzomorphan hydrochloride and 4.1 g (0.033 mol) of (R)-2-methoxy-propionic acid chloride, a mixture of the expected diastereomeric bases is obtained analogously to Example 1, which is separated analogously to Example 2 by column chromatography on 100 times the amount of silica gel. The slower running substance (Rf 0.21) is crystallised out as the hydrochloride.
The title compound is obtained in a yield of 2.54 g with a melting point of 167" (decomp.) and a 4, 9 I AVm 9 SpeC~ZC rot a- ion OL [c 98 6R. (c E0) Uv 4..1.G2 Example 6 /2 (IS,5SR,2:~ 2t ,3'-d-ydoy321(2-ne
OXY
SPrOPYl)-,9-riehl6-bzo rpa hydrochloride The faster running subst, Ca (Rt 0.9) separcated in' Example dii peipttd as the hydrochloride analogouslEy to ExampJ.e 2 :The title, compounid is j obtained in~a yield of. 212s. g (42.710 with a mlti poinrt of 2511T (decomp.) and with a speii o o of [a135= (c 0-.S R)c~ 3 2L is 4.2 CQMOroud nfq I tvne -1 nreparead acga-rdiria to, 4:2. Example 62 -2 1 I*dxoxy- 2- (2 -tetoxyety.) 9trimetbvl 6, 7 -h ezomorphan, bydrob -o1MC'le g(0.003 tuol) of -1hdov-,,-rmehl6i benzomorphan, 0.72 qg(0.0075 mol) of 2 -me~thoxyethylcbJ oride, 0.11g 0 D72.l of sodiu=- iodide jan4.
0.95 g (0.0113 mol) of solium hydrogen carbonate are stirred in 2.0 ml ot absollite ca.irethylormamide at 9S!C f or 23 hours. The reacti 3n mnixture is e-moorated. d~wa, in a rotaryr evaporator, finally at 950C under a tCotal water jet vacuumt. The residue is shaken with 25 ml :of.
30. water and 2S ml of dichloronethane and the aotieous Paa~e, separated. off is axtat once more Vwith. 10'y1 Of dichloromethane. The comLine6. extrJ-acts are 'washed it water, dried with sod-itu sulphate and, after Jfiltratoft of the drying agent, as dencribed above, evaporated i.own fi vacuo.
SAS S 58a- ~~rtinresicu.e consisting of thie free base df the title compoundisd sled in of mta iad after acidification wit 2Q) Wr the solution is'Nixed with dietbyl ether iunti twebidity is just settingi!.
When left to stand fox, out 12 hours in the refrigerator the title cmopound crystall~ises out, is suction filtered, washe with a mixture oT ethanol ;ana ether and dried at 80OC- The title d 6.
9 6 66*6 S *9 9* S 6 S 6 6565 *6 6 6* 0*66*6 S 6
S
6.60 6* 6 S. 6
S
*5
S
6 5* 6 S 6 *5 6 (*66 ~~Q7 59 compound is obtained in a yield of 0.48 g (43.5% of theory) with a melting point of 247*C (decomp.).
to 3 4.2.2 Example ft (-)-(1R,5S,2"R)-21-hydroxy-2-(2-methoxypropyl) 9-trimethyl-6, 7-benzomorphan hydrochloride a) Preparation of the alkylating agent Dy reduction of the (+)-(R)-2-methoxy-propionic acid known from the prior drt with lithium aluminium hydride (LiAlH 4 the -2-mxethoxy-propanol is obtained with a boiling point of 70 0 C under a pressure of 76 mbar and 15 a specific rotation of [D~ 5 -15.80 (c =100). The corresponding -2-methoxy-propanol with a boiling point of 70 0 C under a pressure of 76 mbar and a rotation of [a] 25 +16.5' (c 100) is obtained analogously from the equally well known (-)-(S)-2-methoxy-propionic acid.
By reacting (-)-(R)-2-methoxypropanol with ptoluenesulphonic acid chloride in pyridine analogously to R.S. Tipson Org. Chem. 9 (1944) 235] the 2-Imethoxypropyl-p-toluenesulphonate is obtained in the .9 25 form of a yellowish oil with a specific rotation of Ca2=+3.7- (c 100) and analogously, from 5 methoxy-propanol, the corresponding -2methoxypropyl-p-toluenesulphonate is obtained with a rotation of [a2=-3.70 (c 100).
b) Reaction to form the title compound 1.16 g (5 mMol) of (±)-2'-hydroxy-5,9,9-trimethyl-6,7benzomorphan (Example 1) are heated to reflux temperature with 1.83 g (7.5 ml~ol) of (R)-2-methoxypropyl-p-toluenesulphonate, 1.26 g (0.015 mol) of sodium hydrogen carbonate and 1.12 g (7.5 mMol) of sodium .4 1 60 iodide in a mixture of 15 ml of absolute dimethylformamide and 25 ml of absolute tetrahydrofuran for 60 hours with stirring. Then the mixture is worked up analogously to Example 63. A mixture of the two expected diastereomeric bases (2 g) is obtained which can also be prepared by other methods according to Example 1. The mixture is separated by crystallisation of the hydrochlorides as described in Example 1 and the title compound is obtained in a yield of 0.55 g (64.7% of theory) with a melting point of 264*C (decomp.) and a specific rotation of -118.2° (c 1, CH 3 OH). The (+)-(1S,5R,2"R)-diastereomer can be obtained from the mother liquor analogously to Example 2.
15 4.2.3 Example (-)-(lR,5S,2"R)-2-(2-methoxypropyl)-2'-nitro- 5,9,9-trimethyl-6,7-benzomorphan hydrochloride 2.97 g (0.010 mol) of (±)-2'-nitro-5,9,9-trimethyl-6,7- 20 benzomorphan hydrochloride (Example 34) are reacted analogously to Example 64 with 2.68 g (0.011 mol) of (R)-2-methoxypropyl-p-toluenesulphonate, 1.65 g (0.011 mol) of sodium iodide and 2.1 g (0.025 mol) of sodium hydrogen carbonate. The reaction product which 9 25 is isolated as described consists initially of a mixture of the two expected diastereomeric bases (3.2 In order to separate off any by-products this mixture is dissolved in 64 ml of dichloromethane and the solution is filtered through a column containing 64 g of aluminium oxide (activity stage III neutral according to Brockmann). After eluting with a further 128 ml of dichloromethane, the combined eluates are evaporated down in a rotary evaporator, finally at under a total water jet vacuum. The residue (2.4 g) is dissolved in 10 ml of methanol and after acidification with 2.5 N ethanolic hydrochloric acid the solution is mixed with diethylether until it is just beginning to be 61 cloudy. The title compound is crystallised and after standing for 3 days at ambient temperature it is suction filtered, washed with ethanol/ether mixture then with ether and dried at 80*C. The title compound is obtained in a yield of 0.84 g (45.5% of theory) with a melting point of 226°C (decomp.) and a specific rotation of []25 -120° (c 1, CH 3 OH). The stereoisomeric (1S,5R,2"R) compound may be obtained from the mother liquor if desired.
4.2.4 Example 4- S(+)-(lS,5R,2"S)-2-(2-methoxypropyl)-2'-nitro- 5,9,9-trimethyl-6,7-benzomorphan hydrochloride 15 Starting from 2.97 g (0.010 mol) of (±)-2'-nitro-5,9,9trimethyl-6,7-benzomorphan hydrochloride and 2.68 g (0.011 mol) of (S)-2-methoxypropyl-p-toluenesulphonate, the title compound is obtained analogously to Example in a yield o'f 0.96 g (52.0% of theory) with a melting 20 point of 226'C (decomp.) and a specific rotation of +121° (c CH 3 OH). The stereoisomeric (1R,5S,2"S) form can be obtained from the mother liquor analogously to Example 2.
sees 4.2.5 Example 6 (-)-(1R,5S,2,,R)-2-(2-methoxypropyl)-3'-nitro- 9,9-trimethyl-6,7-benzomorphan a) Preparation of the starting compound (±)-3'-nitro-5,9,9-trimethyl-6,7-benzomorphan required here and in other Examples is formed in addition to the (±)-2'-nitro-isomer when 5,9,9-trimethyl-6,7benzomorphan (Example 34) is nitrogenated in a ratio of about 1 3. It is obtained from the mother liquor of the 2'-nitro-isomer, which is crystallised as the hydrochloride, via the base whiph is prepared initially.
62 This is crystallised as the oxalate (melting point 158°C (decomp.)) from ten times the amount of methanol. The oxalate is converted back into the base (not crystallised) which is used for the reaction described below. A sample of the base, crystallised as the methanesulphonate, melts at 242 0 C (decomp.).
b) Reaction to form the title compound 5.2 g (0.02 mol) of (±)-3'-nitro-5,9,9-trimethyl-6,7benzomorphan are reacted analogously to Example 65 with 5.36 g (0.022 mol) of (R)-2-methoxypropyl-ptoluenesulphonate. The reaction product obtained is a mixture of the two expected stereoisomeric bases (8 g) 15 which is purified by filtering over aluminium oxide as described in Example 65 (4.7 g of purified base mixture). In thin layer chromatography (silica gel toluene/ethyl acetate 85:15, developed 3 times) the diastereomers have R -values of 0.81 and 0.85.
20C Separation of 1 g of diastereomer mixture on 300 g of silica gel by column chromatography yields the title compound (100 mg) with an R,-value of 0.81 as a brownish, very viscous oil which does not crystallise.
4.2.6 Example a (+)-(1S,5R,2"R)-2-(2-methoxypropyl)-3'-nitro- 5,9,9-trimethyl-6,7-benzomorphan During the column chromatography of the diastereomer mixture described in Example 67, in addition to (1R,5S,2"R)-form isolated there (Rf 0.81), 100 mg of the (+)-(1S,5R,2"S)-form (Rf 0.85) are also obtained as a brownish, highly viscous oil which does not crystallise.
63 4.2.7 Example 9 (-)-(1R,5S,2"R)-2'-chloro-2-(2-methoxypropyl)-5,9,9-trimethyl-6,7-benzomorphan hydrochloride a) Preparation of the starting compound (±)-2'-chloro-5,9,9-trimethyl-6,7-benzomorphan used here and in other Examples may be prepared from the 2'-nitro analogue (Example 34), for example, by hydrogenating the latter to form the 2'-amino compound (dihydrochloride: melting point 283"C, (decomp.)), and converting this by Sandmeyer reaction into the desired 2'-chloro-compound (hydrobromide: melting point 310°C (decomp.).
b) Reaction to form the title compound
S,-
3.3 g (0.010 mol) of (±)-2'-chloro-5,9,9-trimethyl-6,7benzomorphan hydrobromide and 2.68 g (0.011 mol) of 20 2-methoxypropyl-p-toluenesulphonate are reacted analogously to Example 65 to form a mixture of the two expected diastereomeric bases and purified by filtration over aluminium oxide as described therein. The purified diastereomer mixture is separated analogously to Example .i 25 1 by crystallisation of the hydrochlorides. The title compound is obtained in a yield of 0.27 g (15.1% of Stheory) with a melting point of 287°C (decomp.) and a rotation of [a]25= -102.6° (c 1, CH 3
OH).
4.2.8 Example M (+)-(1S,5R,2"R)-2'-chloro-2-(2-methoxypropyl)- 5,9,9-trimethyl-6,7-benzomcrphan hydrochloride The mother liquor tf Example 69 is evaporated down and the residue is dissolved with a barely sufficient quantity of boiling methanol. After the addition of diethylether until the mixture is beginning to be cloudy 64 and after simultaneous crystallisation the title compound is obtained. After standing for about 12 hours at ambient temperature this title compound is suction filtered, washed with ethanol/ether 1:1 and then with ether and dried at 80*C. Yield 0.56 g (31.3% of theory) melting point: 289*C, specific rotation: +67.9*.
4.2.9 Example 7a (+)-(lS,5R,2"S)-2'-chloro-2-(2-methoxypropyl)- 5,9, 9-trimethyl-6, 7-benzomorphan hydrochloride 9 Starting from 3.3 g (0.010 mol) of (+)-2'-chloro-5,9,9- *~***trimethyl-6,7-benzomorphan and 2.68 g (0.011 mol) of 15 (S)-2-methoxypropyl-p-toluenesulphonate the title compound is obtained analogously to Example 69 in a yield of 0.41 g (22.9% of theory) with a melting point of 288*C (decomp.) and a specific rotation of +l101. 7 1, CH 3 OH) 4.2.10 Example :A 5S, -2 '-chloro-2- (2-methoxypropyl) 9, 9-trimethyl-6, 7-benzomorphan hydrochloride From the mother liquors of Example 71 the title compound 9.9 is obtained analogously to Example 70 in a yield of V, 0.75 g (41.9% of theory) with a melting point of 288*C and a specific rotation of -a5 6 8. 6 (c 1, CH 3 OH) 4.3 Compounds of type (1)i prepared accordincf to process 1.3 4.3.1 Example W (-)-(lR,5S,2V'S)-2'-methoxy-2-(2-methoxypropyl).-5,9,9-trimethyl-6,7-benzomorphan methanesulphonate 65 0.68 g (2 mMol) of (-)-(lR,5S,2"S)-2'-hydroxy-2-(2methoxypropyl) -5,9,9-trimethyl-6,7-benzomorphan -hydrochloride (Example 4) are placed in 20 ml of absolute dimethylformamide and, whilst cooling with ice and stirring, 0.13 g of 77% sodium hydride suspension in paraffin (4.2 mMol) are added thereto. After 30 minutes stirring, 0.31 g (2.2 mMol) of methyliodide, dissolved in 5 ml of dimethylformamide, are added dropwise within minutes. The mixture is then stirred for a further 3 hours at ambient temperature and evaporated down in the rotary evaporator, finally at 95°C under a total water jet vacuum. The residue is shaken with 25 ml of dichloromethane and 25 ml of water. The aqueous phase separated off is extracted once more with 15 ml of 15 dichloromethane. After washing with 15 ml of water the combined extracts are evaporated down and the residue is crystallised as the methanesulphonate analogously to Example 28. The title compound is obtained in a yield of 0.38 g with a melting point of 150-152°C 20 (decomp.) and a specific rotation of [Ca] -68.7° (c 1= CH 3
OH).
4.3.2 Example (1S, 5R, 2"R) -2'-methoxy-2-(2-methoxypropyl)-5,9,9-trimethyl-6,7-benzomorphan methanesulphonate Starting from 0.68 g (2 mMol) of hydroxy-2-(2-methoxypropyl)-5,9,9-trimethyl-6,7benzomorphan hydrochloride (Example the title compound is obtained analogously to Example 73 in a yield of 0.38 g (46.0% of theory) with a melting point of 150-152°C (decomp.) and a specific rotation of S +67.2° (c 1, CHOH).
66 4.3.3 Example 7 (-)-(1R,5S,2"R)-2'-ethoxy-2-(2-methoxypropyl)- 5,9,9-trimethyl-6,7-benzomorphan methanesulphonate Starting from 0.34 g (1 mMol) of hydroxy-2-(2-methoxypropyl)-5,9,9-trimethyl-6,7benzomorphan hydrochloride (Example 1) and 0.17 g (0.0011 mol) of ethyliodide the title compound is obtained analogously to Example 73 in a yield of 0.30 g (70.2% of theory) with a melting point of 146-148°C (decomp.) and a specific rotation of -93.4° (c 1, CH 3
OH).
7$ 15 4.3.4 Example S6 (-)-(lR,5S,2"R)-2'-acetoxy-2-(2-methoxypropyl)-5,9,9-trimethyl-6,7-benzomorphan methanesulphonate 20 0.68 g (2 mMol) of (-)-(1R,5S,2"R)-2'-hydroxy-2-(2methoxypropyl)-5,9,9-trimethyl-6,7-benzomorphan hydrochloride (Example 1) are dissolved in 15 ml of absolute dichloromethane. After the addition of 0.51 g mMol) of triethylamine the solution is mixed with 25 0.19 g (2.4 mMol) of acetylchloride dissolved in 5 ml of dichloromethane, with stirring, at ambient temperature, over a period of 10 minutes. Then the resulting mixture is stirred for a further 2 hours at ambient temperature.
It is then washed three times with 10 ml of ice water, dried with sodium sulphate and, after the drying agent has been iltered off, the residue is evaporated down (rotary evaporator, finally at a temperature of under a total water jet vacuum).
The residue, which consists of the free base of the title compound (0.6 g, 1.74 mMol), is dissolved in 3 ml of ethanol and acidified to just pH 4 by the addition of s> v- 0 r r" v 67 methanesulphonic acid (0.16 g, (1.74 mMol) in 3 ml of ethanol). After the addition of diethylether until the mixture is just turning cloudy the title compound crystallises and, after being left to stand for about 12 hours in the refrigerator, it is suction filtered, washed with ethanol/ether 1:2 and dried at 80*C. Yield 0.7 g (79.3% of theory), melting point: 183-184'C (decomp.), [2 5 -83.9" (c 1, CH OH).
7', 4.3.5 Example (+)-(1S,5R,2"S)-2'-acetoxy-2-(2-methoxypropyl)-5,9,9-trimethyl-6,7-benzomorphan methanesulphonate starting from 0.68 g (0.002 mol) of hydroxy-2-(2-methoxypropyl)-5,9,9-trimethyl-6,7benzomorphan hydrochloride (Example 3) the title compound is obtained analogously to Example 76 in a yield of 0.6 g (68.0% of theory) with a melting point of 183-1840C (decomp.) and a specific rotation of []25
D
+82.8 (c 1, *27 *99 4.3.6 Example 7tA (-)-(1R,$S,2"S)-2'-acetoxy-2-(2-methoxypropyl)-5,9,9-trimethyl-6,7-benzomorphan .r methanesulphonate Starting from 0.68 g (0.002 mol) of hydroxy-2-(2-methoxypropyl)-5,9,9-trimethyl-6,7benzomorphan hydrochloride (Example 4) the title compound is obtained analogously to Example 76 in a yield of 0.58 g (65.7% of theory) with a melting point of 183*C (decomp.) and a specific rotation of 2= -57.1' (c 1, CH 3
OH).
p 1) 1 4.3.7 68 Example TA 5R, 2"R) -acetoxy-2- (2-methoxypropyl) 9-trimethyl-6 ,7-benzomorphan methanesuiphonate Starting from 0.68 g (2 mMol) of hydroxy-2- (2-methoxypropyl) 9, 9-trimethyl-6, 7benzomorphan hydrochloride (Example 2) the title compound is obtained analogously to Example 76 in a yield of 0.67 g 9% of theory) with a melting point of l83*C and a specific rotation +58.20 (c 1, CH 3
OH).
SO
S S 0*
S*
S 9
*SSS
.6 S
S.
9
S
4.3.8 Example D 5S,2"R) -2-(2-methoxypropyl) propionoxy-5, 9, 9-trimethyl-6, 7-benzomorphan methanesulphonate *5 S0 0000
S..
*0.0 Starting from 0.34 g (1 mMol) of hydroxy-2- (2-methoxypropyl) 9-trimethyl-6, 7benzomorphan hydrochloride (Example 1) and 0.15 g (1.1 mMol) of propionic acid anhydride, the title compound is obtained analogously to Example 76 in a yield of 0.21 g (46.1% of theory) with a melting point f 1 50 (d com and a specific rotation of [a25 -78.3* (c 1, CH 3
OH).
4.3.9 Example 8A (-)-(lR,5S,2"R)-2-(2-methoxypropyl)-5,9,9trimethyl-6, 7-benz omorphan hydrochloride (-)-(lR,5S,2"R)-2-(2-methoxypropyl)-2'-(l- 9-trimethyl-6, 7benzomorphan hydrochloride 1.36 g (4 Mol) of (-)-(lR,5S,2"1R)-21-hydroxy-2-(2methoxypropyl) 9-trimethyl-6, 7-benizomorphan 69 hydrochloride (Example 1) are refluxed with 0.79 g (4.4 mMol) of 5-chloro-l-phenyltetrazole and 1.36 g (0.01 mol) of dry, finely powdered potassium carbonate in 78 ml of absolute acetone for 6 days with stirring.
Then the solution is evaporated down and the residue is mixed with 50 ml of water. It is extracted twice with ml of dichloromethane and the combined extracts are washed with 15 ml of water. After drying with sodium sulphate and filtering off the drying agent the reaction mixture is evaporated in a rotary evaporator, finally at under a total water jet vacuum. The residue is dissolved with 5 ml of ethanol and, after acidifying .W with ethanolic hydrochloric acid, mixed with diethylether until just turning cloudy. The 15 intermediate product crystallises out and, after stan;1ing for about 12 hours in the refrigerator, is ,suction filtered, washed with an ethanol/ether mixture then with ether and dried at 80*C. Yield 1.67 g (86.3% of theory), melting point 241*C (decomp.).
b) Hydrogenation of the intermediate product to obtain the title compound S The intermediate product (1.67 g, 3.5 mMol) is i 25 hydrogenated in he presence of 0.7 g of palladium/charco l in 70 ml of glacial acetic acid under a hydrogen pressure of 5 bar and at ambient temperature until fully reacted (6 10 hours). Then the catalyst is removed by suction filtering, the filtrate is evaporated down and the residue, after being mixed with ml of water and excess ammonia, is extracted with dichloromethane (twice with 25 ml). The combined extracts are washed with water, dried with sodium sulphate and evaporated down after the drying agent has been filtered off in a rotary evaporator, finally at under a full water jet vacuum. The residue is crystallised as the hydrochloride analogously to Example 70 2. The title compound is obtained in a total yield of g (38.5% of theory) with a melting point of 225°C (decomp.) and a specific rotation of -101.5° (c 1, CH3OH).
4.3.10 Example 8 (+)-(1S,5R,2"S)-2-(2-methoxypropyl)-5,9,9trimethyl-6,7-benzomorphan hydrochloride Starting from 1.36 g (0.004 mol) of hydroxy-2-(2-methoxypropyl)-5,9,9-trimethyl-6,7-" benzomorphan hydrochloride (Example 3) the title compound is obtained, analogously to Example 1 by means of the corresponding intermediate product (1.65 g, 85.1% of theory, melting point 241" (decomp.)), in a total yield of 0.64 g (49.4% of theory) with a melting point of 225°C (decomp.) and a specific rotation of +106.9° (c 1, 20 4.3.11 Example s 0 (-)-(lR,5S,2"S)-2-(2-methoxypropyl)-5,9,9trimethyl-6,7-benzomorphan oxalate 0se Starting from 1.36 g (4 mMol) of 26 hydroxy-2-(2-methoxypropyl)-5,9,9-trimethyl-6,7benzomorphan hydrochloride (Example 4) the title compound is obtained in the form of the free base (0.7 g) via the corresponding intermediate product (1.73 g, 89.4% of theory, melting point 218.5'C (decomp.). This base is dissolved with 2 ml of isopropanol and mixed with the corresponding molecular quantity of oxalic acid (0.22 The title compound is crystallised while 50 ml of diethylether are gradually added with stirring. After being kept for about 12 hours in the refrigerator the mixture is suction filtered, washed with isopropanol/ether, then with ether and dried at 80"C. The title compound is obtained in a <a <4 11 71 :*Vo 0 a 0 :0.:e %6 *5 0 00 go to 0 .06:: ,r yield of 0.8 g (53.0% of theory) with a melting point of 135'C (decomp.) and a specific rotation of 5 -60.00 (c 1, CH 3 0H).
4.3.12 Example 8 (+)-(iS,5R,2"R)-2-(2-methoxypropyl)-5,9,9trimethyl-6,7-benzomorphan oxalate Starting from 1.36 g (4 mMol) of hydroxy-2-(2-methoxypropyl)-5,9,9-trimethyl-6,7benzomorphan hydrochloride (Example 2) the base of the title compound is obtained analogously to Example 1 via the corresponding intermediate product (1.65 g, 85.1% of theory, melting point 217 0 C (decomp.)), and is crystallised out as the oxalate analogously to Example 83. Total yield 0.6 g (39.7% of theory), melting point: 135 0 C (decomp.), specific rotation: [C]2 5 +60.2° (c 1, 874 4.3.13 Example 8& (-)-(1R,5S,2"R)-2'-acetamido-2-(2-methoxypropyl)-5,9,9-trimethyl-6,7-benzomorphan hydrochloride 25 0.70 g (1.87 mmol) of methoxypropyl)-5,9,9-trimethyl-6,7-benzomorphan dihydrochloride (Example 34) are dissolved in 20 ml of absolute dichloromethane, mixed with 0.76 g (7.4 mMol) of triethylamine and then, with stirring, at ambient temperature, 0.17 g (2.1 mMol) of acetylchloride dissolved in 5 ml of dichloromethane are added dropwise thereto. The mixture is then refluxed for 1 hour, cooled, washed three times with 10 ml of water, dried with sodium sulphate and, after the drying agent has been filtered off in a rotary evaporator, finally at 800C under a full water jet vacuum, concentrated by evaporation. The residue is dissolved in 2 ml of /dr
AMA
rr 72 6S9@
C*
6@ 0
OSO@
0*
S
OS 0 C S C S SO S. C C SC CO C erg.
methanol and after acidification with 2.5 N ethanoplic hydrochloric acid the solution is mixed with diethylether until just beginning to go cloudy. The crystals precipitated are suction filtered (after standing for about 12 hours in the refrigerator), washed with an ethanol/ether mixture then with ether and dried at 80°C. The title compound is obtained in a yield of 0.49 g (68.8% of theory) with a melting point of 252 C (decomp.) and a specific rotation of 2 -108.2° (c 1, CH 3 OH) 4.3.14 Example FS (+)-(lS,5R,2"S)-2'-acetamido-2-(2-methoxypropyl)-5,9,9-trimethyl-6,7-benzomorphan 15 hydrochloride Starting from 1.07 g (2.58 mMol) of amino-2-(2-methoxypropyl)-5,9,9-trimethyl-6,7benzomorphan hydrochloride (Example 36) the title 20 compound is obtained analogously to Example 85 in a yield of 0.73 g (74.3% of theory) with a melting point of 2494C (decomp.) and a specific rotation of +109.5 (c 1, 4.3.15 Example 7 (-)-(1R,5S,2"S)-2'-acetamido-2-(2-methoxypropyl)-5,9,9-trimethyl-6,7-benzomorphan 1.09 g (0.0026 mol) of methoxypropyl)-5,9,9-trimethyl-6,7-benzomorphan dihydrochloride are reacted analogously to Example The reaction product is isolated as described therein and crystallised from 0.5 ml of isopropanol and 5 ml of petroleum ether. The title compound is obtained in a yield of 0.7 g (76.4% of theory) with a melting point of 128*C and a specific rotation of [a]25= -89.3' (c 1, CH30H 1 N HC1 1:1).
A l (A F& ,4* -d -ri 73 4.3.16 Example S8 (+)-(IS,5R,2"R)-2'-acetamido-2-(2-methoxypropyl)-5,9,9-trimethyl-6,7-benzomorphan Starting from 1.11 g (2.5 mMol) of amino-2-(2-methoxypropyl)-5,9,9-trimethyl-6,7benzomorphan dimethanesulphonate (Example 35), the title compound is obtained analogously to Example 87 in a yield of 0.37 g (47.7% of theory) with a melting point of 129°C and a specific rotation of [a] 25 +89.9° (c 1,
CH
3 OH 1 N HC1 1:1).
4.3.17 Example 8* 2"R) -3'-bromo-2-hydroxy-2-(2- 15 methoxypropyl)-5,9,9-trimethyl-6,7benzomorphan hydrochloride o**
S
0.85 g (2.5 mMol) of (-)-(1R,5S,2"R)-2'-hydroxy-2-(2methoxypropyl)-5,9,9-trimethyl-6,7-benzomorphan 20 hydrochloride (Example 1) are suspended in 30 ml of glacial acetic acid. 0.15 ml (0.47 g, 2.9 mMol) of bromine are added to the suspension with stirring at @fee ambient temperature. After 2 hours' stirring the mixture is evaporated down in a rotary evaporator, finally at 80*C under a total water jet vacuum. The residue is mixed with 25 ml of water and 25 ml of **oO* dichloromethane with ammonia in excess, with agitation.
The aqueous phase separated off is extracted once more with 15 ml of dichloromethane, the combined extracts are washed with 15 ml of water, dried with sodium sulphate and, after the drying agent has been filtered off as described above concentrated by evaporation. The residue (1 g) is purified by chromatography over a column containing 250 g of silica gel analogously to Example 2, using a mixture of dichloromethane, methanol and conc. amnonia (90:10:0.5). The eluates containing the pure substance are evaporated down as above and the 74 residue is crystallised as the hydrochloride analogously to Example 2. The title compound is obtained in a yield of 0.75 g (65.8% of theory) with a melting point of 245°C (decomp.) and a specific rotation of [c] 25 -82.5" (c CH 3
OH).
SY
4.3.18 Example e9 (+)-(lR,5R,2"R)-2'-hydroxy-l l -nitro-2-(2methoxypropyl)-5,9,9-trimethyl-6,7benzomorphan hydrochloride O 0.85 g (2.5 mMol) of (-)-(1R,5S,2"R)-2'-hydroxy-2-(2methoxypropyl)-5,9,9-trimethyl-6,7-benzomorphan hydrochloride are suspended in 30 ml of glacial acetic 15 acid at 20°C and 0.18 ml (0.25 g) of 65% nitric acid (2.6 mMol of HNO 3 are added with stirring. Within about 10 minutes a clear yellow solution is formed which turns brown after another 5 minutes and begins to turn cloudy as a crystalline compound is precipitated. After a 20 reaction time of 1 hour in total the mixture is suction filtered and washed with a glacial acetic acid/diethylether mixture then with ether and e* dried at 80*C. The crystals (0.35 g) are dissolved in a hot methanol/water mixture (17.5 ml 1.75 ml) and 25 diethylether (40 ml) is added to the sclution. After cooling in an ice bath the substance which crystallises out is suction filtered, washed with ether and dried at The title compound is obtained in a yield of 0.32 g (33.3% of theory) with a melting point of 245°C (with gradual brown coloration and decomposition); specific rotation 25 +87.0 (c 1, CH 3
OH).
75 go 4.3.19 Example 9% (-)-(lR,5S,2"R)-2'-hydroxy-2-(2-methoxypropyl)-3'-nitro-5,9,9-trimethyl-6,7benzomorphan hydrochloride The nitrogenation described in Example 90 produces from the starting compound (Rf 0.57) the l'-nitro-derivative described above (Rf 0.45), the isomeric 3'-nitroderivative (Rf 0.72) and the 1',3'-dinitro-derivative (Rf 0.10) (TLC: silica gel chloroform/methanol/conc, ammonia 90:10:0.5). The A mother liquor remaining (Example 90) after the suction filtering of the 1'-nitro compound is evaporated down
S.
and the residue is converted into the free bases. These 15 are dissolved in 10 ,f dichloromethane and the yellow solution is filterei 'er 25 g of aluminium oxide (activity III, neutral). The solution is eluted with dichloromethane until the eluate is no longer a strong yellow colour and the eluate is then evaporated down.
•S o S. 20 The residue (0.35 g) is dissolved in 2.5 ml of ethanol and, after acidification with ethanolic hydrochloric acid, diethylether is added to the solution until it is just beginning to turn cloudy. After it has stood for about 12 hours in the refrigerntor it is suction O 25 filtered, washed with an ethanol/ether mixture and dried at a temperature of 80°C. The title compound is obtained in a yield of 0.40 g (41.6% of theory) with a melting point of 229-230 0 C (decomp.) and a specific rotation of -110.1° (c 1, CHOH) 4.3.20 Example W (+)-(lR,5R,2"R)-2',3'-dinitro-2'-hydroxy-2-(2methoxypropyl)-5,9,9-trimethyl-6,7benzomorphan hydrochloride 1.52 g (5 mMol) of (-)-(1R,5S,2"R)-2'-hydroxy-2-(2methoxypropyl)-5,9,9-trimethyl-6,7-benzomorphan r 76 .0*0 (Example 1) are dissolved in 3 ml of glacial acetic acid and, whilst stirring at 3-4°C, a mixture of 3.4 ml of glacial acetic acid and 5.42 ml of 100% nitric acid are added to the solution within 1.5 hours. The resulting mixture is stirred for a further 3 hours at ambient temperature. Then the yellow reaction mixture is poured into 50 g of ice water, the solution is made ammoniacal and extracted three times with 20 ml of dichloromethane.
After the combined extracts have been washed with water and dried over sodium sulphate and the drying agent has been filtered off, the reaction mixture is evaporated down in a rotary evaporator, finally at 80*C under a total water jet vacuum. The residue is crystallised from an ethanol/ether mixture. The title compound is obtained in a yield of 1.0 g (46.5% of theory) with a melting point of 300*C (decomp.) and a specific rotation of [a] 5 +27.9° (c 1, CH 3
OH).
4.3.21 Example 20 (-)-(lR,5R,2"R)-l'-amino-2'-hydroxy-2-(2methoxypropyl)-5,9,9-trimethyl-6,7benzomorphan hydrochloride 0.35 g (1.0 mMol) of (+)-(1R,5R,2"R)-2'-hydroxy-2-(2- 25 methoxypropyl)-l'-nitro-6,7-benzomorphan hydrochloride (Example 90) are hydrogenated in 40 ml of methanol in the presence of 0.1 g of palladium/charcoal Pd) for 4 hours under a hydrogen pressure of 5 bar at ambient temperature. After the catalyst has been filtered off the reaction mixture is evaporated down in a rotary evaporator, finally at 80°C under a total water jet vacuum and the residue is crystallised from 10 ml of ethanol. After cooling in an ice bath the crystals are suction filtered, washed with an ethanol/ether mixture and dried at 80°C. The title compound is obtained in a yield of 0.17 g (52.7% of theory) with a melti;g point S of 282*C (after slow decomposition from 250*C) and a f 4>:T C 77 specific rotation of -128.3* (c 1, CH OH) 3 4.3.22 Example i (-)-(1R,5S,2"R)-3'-amino-2'-hydroxy-2-(2methoxypropyl)-5,9,9-trimethyl-6,7benzomorphan hydrochloride Starting from 0.39 g (1.0 mMol) of hydroxy-2-(2-methoxypropyl)-3'-nitro-5,9,9-trimethyl- 6,7-benzomorphan hydrochloride (Example 91) the title compound is obtained analogously to Example 93 in a yield of 0.27 g (76.1% of theory) with a melting point of 268*C (decomp.) and a specific rotation of [D3] 5 -99.70 (c 0.5,
C
4.3.23 Example S (-)-(1R,5R,2"R)-1',3'-diamino -2'-hydroxy-2-(2minethoxypropyl)-5,9,9-trimethy-6,7benzomorphan hydrochloride Starting from 0.70 g (1.63 mMol) of 1',3'-dinitro-2'-hydroxy-2-(2-methoxy-propyl)-5,9,9trimethyl-6,7-benzomorphan hydrochloride (Example 92) the title compound is obtained analogously to Example 93 S 25 in a yield of 0.20 g (33.2% of theory) With a melting point of 228 0 C (decomp.) and a specific rotation of -111.7 (c 0.5, CH OH) D 3 4.3.24 Example W (-)-(l1R,5S,2"R)-3'-amino-2 -(2-methoxypropyl)- 5,9,9-trimethyl-6,7-benzomorphan The diastereomixture obtained according to Example 67 consisting of and methoxypropyl)-3'-nitro-5.9, -trimethyl-6,7-benzomorphan (3.7 g) is dissolved in 75 ml of methanol and V440 hydrogenated in the presence of 0.8 g of
%'T
"51 78 palladium/charcoal Pd) under a hydrogen pressure of bar and a temperature of 20"C until the uptake of hydrogen ceases (about 3 hours). In thin layer chromatography (silica gel 60, chloroform/methanol/conc.
ammonia 90:10:0.5) it is found that the 3'-nitro compounds (Rf 0.73) have reacted completely to form the corresponding 3'-amino-compounds (Rf 0.61). After the catalyst has been filtered off the reaction mixture is evaporated down in a rotary evaporator, finally at under a total water jet vacuum. The residue (3.1 g) is subjected to column chromatography on 600 g of silica gel analogously to Example 2. The separation of the diastereomeric 3'-amino-compounds is monitored by thin layer chromatography (silica gel chloroform/methanol/conc. ammonia 95:5:0.1, developed twice). The title compound with the smaller Rf value of 0 0.63 is obtained in a yield of 0.95 g as the evaporation residue of the corresponding eluates with a specific rotation of [a]2 5 -39.8" (c 1, CH 3 OH) which has hitherto resisted all attempts at crystallisation.
4.3.25 Example (+)-(IS,5R,2"R)-3'-amino-2-(2-methoxypropyl) 5,9,9-trimethyl-6,7-benzomorphan In the separation of the diastereomers by column chromatography described above (Example 96) the substance with the greater Rf Value of 0.69 obtained is the title compound in the form of the evaporation residue of the eluates in question (1.0 g, specific rotation: [a]25= +104 (c 1, CH 3 which has hitherto withstood all attempts at crystallisation.
p,1 79 4.3.26 Example
E
(+)-(1S,5R,2"S)-3'-amino-2-(2-methoxypropyl)- 5,9,9-trimethyl-6,7-benzomorphan a) 3'-nitro-precursor (mixture of diastereomers) Starting from 5.2 g (0.02 mol) of (±)-3'-nitro-5,9,9trimethyl-6,7-benzomorphan and 5.36 g (0.022 mol) of (S)-2-methoxypropyl-p-toluene-sulphonate and a mixture of the two expected diastereomeric bases is obtained analogously to Example 67 and is purified by filtration over aluminium oxide, resulting in 4.7 g of purified base mixture.
b) 3'-amino-compounds (mixture of diastereomers) The 3'-nitro-precursor (4.7 g of purified mixture of diastereomers) is hydrogenated analogously to Example 96 to form the corresponding 3'-amino compounds (S.7 g of S 20 mixture of diastereomers).
c) Separation of the title compound by column chromatography 25 The mixture of diastereomeric 3'-amino-compounds (3.7 g) is separated by column chromatography on silica gel analogously to Example 96. The title compound with the smaller Rf value of 0.63 is obtained in a yield of 1.0 g as the evaporation residue of the eluates in question with a specific rotation of +40.50 (c 1, CHOH), which has hitherto withstood all attempts at crystallisation.
80 4.3.27 Example 9 (-)-(1R,5S,2"S)-3'-amino-2-(2-methoxypropyl)- 5,9,9-trimethyl-6,7-benzomorphan In the column chromatography described above (Example 98) the title compound is obtained as the second substance with the greater Rf value of 0.69, in the form of the evaporation residue of the eluates in question in a quantity of 1.1 g, specific rotation: [a] 25 -105" (c 1, CHOH), and has not hitherto crystallised.
4.3.28 Example 1- '-acetamido-2-(2-methoxypropyl)-5,9,9-trimethyl-6,7-benzomorphan 0.95 g (3.14 mMol) of methoxypropyl)-5,9,9-trimethyl-6,7-benzomorphan (Example s 96) are acetylated analogously to Example 85. The acetylation product is purified by filtration over S 20 aluminium oxide analogously to Example 65. In thin layer chromatography (silica gel chloroform/methanol/conc. ammonia 90:10:0.5) the starting compound has an Rf value of 0.64 and the S acetylation product has an Rf value of 0.57. The evaporation residue (0.69 which has hitherto resisted all attempts at crystallisation, has a specific rotation of -53.6° (c 1, CH3OH).
o 4.3.29 Example te (+)-(l~,5R,2"R)-3'-acetamido-2-(2-methoxypropyl)-5,9,9-trimethyl-6,7-benzomorphan oxalate Starting from 1.0 g (3.31 mMol) of amino-2-(2-methoxypropyl)-5,9,9-trimethyl-6,7benzomorphan (Example 97) the title compound is obtained analogously to Example 100. The evaporation residue of 81 the substance purified over aluminium oxide (0.5 g) is crystallised in the form of the oxalate analogously to Example 83. The title compound is obtained in a yield of 0.4 g (27.8% of theory) with a melting point of 148*C (decomp.) and a specific rotation of 5 +39.3 (c 1, CH 3 0H).
IVI
4.3.30 Example 1;2 (+)-(1S,5R,2"S)-3-acetamido-2-(2-methoxypropyl)-5,9,9-trimethyl-6,7-benzomorphan Starting from 1.0 g (3.31 mMol) of amino-2-(2-methoxypropyl)-5,9,9-trimethyl-6,7benzomorphan (Example 98) the title compound is obtained 15 analogously to Example 100,',s a non-crystallising evaporation residue (0.6 g, 41.7% of theory) with an R 9 value of 0.57 and a rotation of 52.80 (c 1, 0* C 4.3.31 Example (-)-(1R,5S,2"S)-3'-acetamido-2-(2-methoxypropyl)-5,9,9-trimethyl-6,7-benzomorphan oxalate 25 Starting from 0.95 g (3.14 mMol) of amino-2-(2-metho:ypropyl)-5,9,9-trimethyl-6,7benzomorphap (Example 99) the title compound is obtained analogously to Example 101 in a yield of 0.7 g (51.1%) 9..
fi. *with a melting point of 148"C (decomp.) and a specific rotation of [a]2 5 -39.2* (c 1, CH 3
OH).
0'3 4.3.32 Example B& (-)-(1R,5S,2"R)-3'-methoxy-2-(2-methoxypropyl)-5,9,9,2'-tetramethyl-6,7-benzomorphan hydrochloride Starting from 0.71 g (2 mMol) of 82 hydroxy-2- (2-methoxypropyl) -5,9,9,2 '-tetramethyl-6,7benizomorphan hydrochloride (Example 53) the title compound is obtained analogously to Example 73 in a yield of 0.38 g with a melting point of 221-224'C and a specific rotation of [a25 82.6' (c 1, CH 3 OH) )04 4.3.33 Example 1#6 5R, 2"R) -3 '-methoxy-2- (2-methoxypropyl) -tetramethyl-6,7-benzomorphan hydrochloride Starting from 0.71 g (2 mMol) of hydroxy-2-(2-methoxypropyl) -5,9,9,2 '-tetramethyl-6,7- 15 benzomorphan hydrochloride (Example 54) the title **compound is obtained analogously to Example 73 in a yield. of 0.44 g as an amorphous powder with a specific rotation of 15=+4 2.2 (c 1, CHOH) 20 4.3.34 Example 1:@ '-methoxy-2-(2-mnethoxy- ,propyl) 9,9, 2 -tetramethyl-6, 7-benzomorplhan ***hydrochloride Starting from 0.71 g (2 mMol) of hydroxy-2-(2-methoxypropyl) -5,9,9,2 '-tetramethyl-6,7benzomorphan hydrochloride (Example 55) the title compound is obtained analogously to Example 73 in a yield of 0.40 g with a melting point of 221-224 0 C and a specific rotation of +81]7D (c CH 3
OH).
-83 4.3.35 Example V7 (-)-(lR,5S,2"S)-3'-methoxy-2-(2-methoxypropyl) 9,9, 2 -tetramethyl-6, 7-benzomorphan hydrochloride Starting from 0.71 g (2 m~ol) of hydroxy-2- (2-methoxypropyl) -5,9,9,2 '-tetramethyl-6, 7benzomorphan hydrochloride (Example 56) the title compound is obtained analogously to Example 73 in a yield of 0.42 g as an amorphous powder with a specific rotation of 11 41. 0 (c CH OH).
)0"7 S.4.3.36 Example14 2 '-methoxy-2- (2-methoxypropyl)-5,9,9,3'-tetramethyl-6,7-benzomorphan hydrochloride *Starting from 0.71 g (2 mMol) of hydroxy-2- (2-mi thoxypropyl) -5,9,9 ,3 '-tetramethiyl-6 ,7- 20 benzomorphan hydrochloride (Example 57) the title compound is obtained analogously to Example 73 in a yield of 0.36 g with a melting point of 221-224*C and a specific rotation of [a2=-112.2- (c 1, CH 3 0H) 4.3.37 Example hO!9 5R, 21R) -methoxy-2- (2-methoxypropyl) -tetramethyl-6, 7-benzomorphan hydrochloride Starting from 0.71 g (2 mMol) of hydroxy-2-(2-methoxypropyl) -5,9,9,3 '-tetramethyl-6,7benzomorphan hydrochloride (Example 58) the title compound is obtained analogously to Example 73 in a yield of 0.39 g as an amorphous powder with a specific rotation of [ax]2 5 +72.4* (c 1, 0113011).
84 4.3.38 Example 14* (+)-(1S,5R,2"S)-2'-methoxy-2-(2-methoxypropyl)-5,9,9,3'-tetramethyl-6,7-benzomorphan hydrochloride Starting from 0.64 g (2 mMol) of hydroxy-2-(2-methoxypropyl)-5,9,9,3'-tetramethyl-6,7benzomorphan hydrochloride (Example 59) the title compound is obtained analogously to Example 73 in a yield of 0.45 g with a melting point of 228-229"C and a specific rotation of [C]25= +111.5" (c 1, )~ml /0 4.3.39 Example -e (-)-(1R,5S,2"S)-2'-methoxy-2-(2-methoxypropyl)-5,9,9,3'-tetramethyl-6,7-benzomorphan hydrochloride Starting from 0.71 g (2 mMol) of 20 hydroxy-2-(2-methoxypropyl)-5,9,9,3'-tetramethyl-6,7benzomorphan hydrochloride (Example 60) the title compound is obtained analogously to Example 73 in a yield of 0.40 g as an amorphous powder with a specific rotation of (a]25= -71.8* (c 1, CH 3
OH).
II
4.3.40 Example 1R,5S,2"R)- -hydroxy-2'-methoxy-2-(2- ,9-trimethyl-6,7benzomorphan hydrobromide Starting from 3.56 g (10 mMol) of dihydroxy-2-(2-methoxypropyl)-5,9,9-trimethyl-6,7benzomorphan hydrochloride (Example 61) a mixture of the two isomeric monomethoxy derivatives and the dimethoxy derivative is obtained analogously to Example 73, except with two equivalents of sodium hydride, and this mixture RvkA is separated by column chromatography on 100 times the 4- 85 quantity of silica gel analogously to Example 2 [eluant: dichloromethane/isopropanol/conc. ammonia 97:3:03]. The compound which runs out as the middle substance (Rf 0.73) is crystallised as the hydrobromide. The title compound is obtained in a yield of 0.62 g (15.0%) with a melting point of 212°C (decomp.) and a specific rotation of [a]5 -78.4" (c 0.5; CH 3
OH).
4.3.41 Example (-)-(1R,5S,2"R)-2'-hydroxy-3'-methoxy-2-(2methoxypropyl)-5,9,9-trimethyl-6,7benzomorphan hydrobromide The slower running substance (Rf 0.68) separated off in S 15 Example 112 is precipitated as the hydrobromide. The title compound is obtained in a yield of 0.88 g (21.2%) with a melting point of 235'C (decomp.) and with a specific rotation of -93.1° (c 0.5; i13 20 4.3.42 Example 1-4 (-)-(1R,5S,2"R)-2',3'-dimethoxy-2-(2-methoxypropyl)-5,9,9-trimethyl-6,7-benzomorphan hydrochloride 25 The faster running substance (Rf 0.86) separated off in Example 112 is precipitated as the hydrochloride. The .title compound is obtained in a yield of 0.87 g (22.7%) with a melting point of 193"C (decomp.) and a specific rotation of -93.2" (c 0.5; CHZOH).
D 3 86 4.4 Compounds of type prepared by other methods 114 4.4.1 Example (-)-(1R,5S,2"R)-2'-hydroxy-2-(2-hydroxypropyl)-5,9,9-trimethyl-6,7-benzomorphan hydrochloride g (3.60 mMol) of benzyloxypropyl)-2'-hydroxy-5,9,9-trimethyl-6,7benzomorphan hydrochloride (Example 43) are dissolved in ml of methanol and hydrogenated in the presence of palladium hydroxide on activated charcoal (0.6 g of moist "Pearlman catalyst") under a hydrogen pressure of 5 bar and at a temperature of 70°C until completely reacted (about 6.2 hours). Then the catalyst is filtered off and the filtrate is evaporated down in a rotary evaporator, finally at 80'C under a total water jet vacuum. The residue is dissolved in 10 ml of methanol and 30 ml of diethylether are added to the 20 solution. The crystals precipitated are left to stand for about 12 hours at ambient temperature, then suction filtered, first with an ethanol/ether mixture then with ether, and dried at 80°C. The title compound is obtained in a yield of 1.0 g (85.5% of theory) with a "O 25 melting point of 276* (decomp.) and a specific rotation of [a] 5 -127.4° (c 1, CHOH).
4.4.2 Example se (+)-(lS,5R,2"S)-2'-hydroxy-2-(2-hydroxypropyl)-5,9,9-trimethyl-6,7-benzomorphan hydrochloride Starting from 1.5 g (3.6 mMol) of benzyloxypropyl)-2'-hydroxy-5,9,9-trimethyl-6,7benzomorphan hydrochloride (Example 44) the title compound is obtained analogously to Example 115 in a a7 yield of 1.0 g (85.5% of theory) with a melting point of 87 2760 (decomp.) and a specific rotation of (c 1, CH 3
OH).
4.4.3 Example ;7 (-)-(lR,5S,2"-S)-2'-hydroxy-2-(2-hydroxypropyl) 9-trimethyl-6, 7-benzomorphan hydrochloride The diastereomer remaining in the mother liquor according to Example 44 (3.17 g of evaporation residue) is hydrogenated analogously to Example 115. The title compound is obtained in a yield of 1.5 g (56.2% of theory) with a melting point of 247*C (decomp.) and a specific rotation of [ia]2 5 -8 6.8 (c 1, CH OH).
.4.4.4 Example 3;1 )-(lS,5R,2"IR)-2'-hydroxy-2-(2-hydroxypropyl) 9-trimethyl-6, 7-benzomorphan hydrochloride :::a:The diastereomer remaining in the mother liquor according to Example 43 (3.17 g of evaporation residue) is hydrogenated analogously to Example 115. The title compound is obtained in a yield of 1.5 g (56.2% of 25 theory) with a melting point of 247'C (decomp.) and a *specific rotation of [a]D +86.40 (c 1, CH OH-) 4.4.5 Example 14!S 5S/R, 2"S) -fluoro-2- (2-methoxypropyl) -5,9,9-trimethyl-6,7-benzomorphan oxalate a) Starting compound: (lR/S,5S/R,2"S)-2'-fluoro-2-(2methoxypro'pioinyl) 9-trimethyl-6, 7-benzomorphan (mixture of diastereomers) 3.94 g (0.02 mol) of (+)-2'-nitro-5,9,9-trimiethyl-6,7- 88 benzomorphan hydrochloride are acylated analogously to Example 32 with 2.68 g (0.22 mol) of methoxypropionic acid chlorid i. The acylation product thus obtained (7.0 g) is hydrogenated as described therein to form the corresponding 2'-amino-analogue.
This latter is reacted, using methods known from the prior art Fletcher and M.J. Namkung, Chem. and Ind. 1961, 179] to form the corresponding 2'-fluoro derivative (5.7 This results in a mixture of the expected diastereomers, which cannot be separated by thin layer chromatography (Rf 0.73, silica gel, chloroform/methanol/conc. ammonia 90:10:0.5).
b) Reaction to obtain the title compound 1.58 g (5 mMol) of the precursor are reduced with lithium aluminium hydride (LiAlH 4 to form the title compound analigously to Example 32 and purified by column chromatography on silica gel as described 20 therein. The evaporation residue of the eluates with the purified substance (0.4 g, Rf 0.78) is crystallised as the oxalate analogously to Example 83. The title compound is obtained in a yield of 0.35 g (17.7% of theory) with a melting point of 165 0 C (decomp.) and with a rotaton of 5= (c 1, CH 3 OH). The substance consists of a mixture of the expected diastereomers and (lS,5R2"S)-compound) in a ratio of about 1:1 (determined by IH-NMR spectroscopy).
4.4.6 Example 3, (-)-(1R/S,5S/R,2"R)-2'-fluoro-2-(2-methoxypropyl)-5,9,9-trimethyl-6,7-benzomorphan oxalate a) Starting compound: (1R/S,5S/R,2"R)-2'-fluoro-2-(2methoxypropionyl)-5,99-trimethyl-6,7-benzomorphan g, (mixture of diastereomers) 89 Starting from 2.97 g (0.01 mol) of (±)-2'-nitro-5,9,9trimethyl-6,7-benzomorphan hydrochloride, a mixture of the expected diastereomeric 2'-fluoro-2-(2methoxypropionyl)-5,9,9-trimethyl-6,7-benzomorphans is obtained, using 1.34 g (0.011 mol) of (R)-2-methoxypropionic acid chloride (reaction sequence as in Example 119). These diastereomers cannot be separated by thin layer chromatography (Rf 0.73, silica gel, ibhloroform/methanol/conc. ammonia 90:10:0.5), yield: 2.9 g.
b) Reaction to form the title compound 2.9 g (9.2 mMol) of the above precursor are reduced with 0. 15 lithium aluminium hydride analogously to Example 119 to obtain the title compound. The reaction is purified as described therein. The evaporation residue of the pure fractions (0.9 g) is crystallised as the oxalate analogously to Example 98. The title compound is 20 obtained in a yield of 0.88 g (22.3% of theory) with a melting point of 169°C (decomp.) and a specific rotation of (c 1, CH 3 OH) in the form of a mixture of the expected diastereomers and (1S,5R, 2"R)-compounds).
O
°o S

Claims (3)

  1. 5.55 30 R5 represents aCI P-6 represents a R 7 and R 8 which Utz eachi represent -NTO 2 FE2 -NH(C -N(C 1 -S-a2Jc1) -a (wherain the al 8alkJy2. a ky or aryl group, and. a.y be identical or different, a hydrogen or halogen atom or. 'a C 8 koxy~, -O-acy3., -MN, F1 0 akv) -NE-acyl, ~yor -N group kvl grou-ps may be ietclo U 1. C. C 0 S C C C OR Re Re C C 9 .RC. CC Rh S S CR C C C CR.. .RC. C. C C C Re C C. Re C C RCR CR C B. Re C C C. Re.. C C CRSR 91 and all racemic, enantiomieric aild diastereomeria formns thereof and aiixtuzels thereo f and acid addition salts teef with the exception -E the. race-nic forms of compounds wherein Pj represenits a CIalk ley orC3 ~3 represents a hyd'rog-en atom, C3---alky1 or alkenyl. 9-rouD;i and1 R 3 renresents a h- &rogen atom or a C' -alkvll group; and T' -R~i and -Rs both rersent a nethyl gro~ip and; R~repDreseants aC-al-Kvl or pherayl g-roulp; and. R7 represents. a drogen atom; and Re represents a h- drogen atom, a 21-hydroxy or a 2- 0.-a y Crup or 2' -RI.COQ wherein R111 represents ah ogen atomn, a C-al.kyl, pheny hnV! ,enty or 3 pyridyl group; andt X represenits 0 Compounds as6i claime CFJm 1. wherein. X represents an oxygen or sulphar atom; R11 represents a -methyl, ethyl, propyl, isopropy. 35 I 3 1W *0 S S 5 0 *5 20 S. S S I 0 *500 5 0 S
  2. 9. 0 0*@S*S S 0*S* OS 55 5 SO' S. S. SgOOSS S. 0 S. 0. 00 5050 S S S OS.. 35 .d 4 v 1 00 UU414 ";'J'Ayli4 or phenyl.'groi repbresents a2 a-llyl, propar group; R~renresents a isopropyl gro Rs represents a isorop].groi P.6 repiveselts a or phenyl R 7 rapresen-ts a bhydroxcy, 'owe: group; and Ra represents a hydroxy or a&] 3 comtpou~nd~s as Claim, x represents an R represents a1 R? represents a V- represents a RS represemtS a -92- Ithi, -etLV I, propyl, isopropyl 4y1, phenyl or b iz l C SU a 7drogen aooraC alk nethyl, ethylJ., propyl or nethyl, ethyl, pro-pyl or SIL" nethyl-, ethyl, propyl, i.SO*ropvl brine O-lo eato or la r .k o r h l on 'aor a lo Y rogen atomu or a lower al]&li ~OXYgro~~ inclaim. i 7 La 2 whereirl xy gen 'atom,- Sth.by). or ethyl groupi me VI or etbhyl group; ry]ogen atoza; e-A or etyl grouzp; mi-hyl oretliyl group? U I I.; V -A 4, Ij 4) Q 4j v' 1 A A PVWIA.N acvloxy grouip; ethylI or etb.l Sroup; y~droxyA methyl, methox-v 'I I I ago*S *.00 :.46 69460 R 8 represents a Tk v roxy or lowe-Y 4. Comrpbunds as claim 1 wherei-n A- re~rasents an d RI- represents a i revresents am R~represents a R 4 renresents a met represents a met R6 represents am R7 re~z-esents a h,~ acetoxy2 gc-roup;l rerset a. LY~ hydroxy, methozO compounds as claimned wherein the substituents and. 3 r-position respectiv the R-configUration. G. Comrpounds as claimted rogen atom or a methyl, ethkrl,l a.lko.c group. iaanvon of claimsi t- /9gZ1 atom; ~hyl group;. :hvl group; irogen atom o a;thl ory etrop gI. V. ono lisIt 7 a I on d RO, rel intho 2-osi3 eirgand athe or -aro methyl ha ~im any one of claims 1 to1 as U ItV; r&rSpec ica 7 yi'des ribed iLn any ona: of_ the, A process for the g e~9aration bf a com-bound of. gen-eral formula as aimd n:laa 3 wherein either a) a compotud ot geneiL: fo~mula(2 and R 6 are as de-Eined i'n claim 1 and R 9 and R3IIai6e either as defined n claim I JEor R7 and R" o reprsentgroaps which may be etherifi ',td reduedhalogenateg or nitrated to produce a 6=1,upI RI. or R3 by methods kn~own per s( is rehcted wa'Ltbl al carboxylic acidC der31ative of. genaeral forwula 4 (whrai Yre-oresen~s a leavig-, grouip, caale:..' beinig substituted b a secondary anmino group,. and R1,R-, R ad ar a dfi~d rLclaim, 1) 1 -H5 II, I Kx R 2 R 9 anad the resulting a id tieof formula is subsequtently reduce to obtain the anine o-f qeneral, formula i 4. 4 S 4 *4 4 4 4 4 4. 4 4 4 4**4 4* 4 4 S 4* 4 4 *444
  3. 444. Se 44. *4 9 4*' 4 5* 4 4 4* 4 4 4 4. 4444 4. 4**4 1~ .2 .4, ~i5- and, whaere ~R4R qI., :he s-abstituents R9 and as I. 00 *0*0 else4 V 1to I %XVZI0 .'V4UI-: defined. above a~re defined in claimi thereby obtaizzed or b) a cormond of. qezer a Ii' nv-erted into and R 8 as and the comootmd of f ortia 101 ateld Jformula :R 2 R R R (61 R9 a-ad RIO are as deftined abov-e, ith ar. alk-flating- agent Of (wherei n Z represents a leavig substituted by a secondaryi, R and X are as defined in he tertiary ami-Lne of forzaula, IG R Z-CH2. (whereinR 4 _RS, R 6 ,]I in a) is reacted w-2 general forniula (5) group, which can be amino group, and RI-, claim to o0btain and, where necessar the subStituents R9 and R-IO defined above are coxmerted in~to ZL7 and Ps as definecl in claim 1, Lid the compound of fornitld tJ2erebv obtained is isolated- aitdI n 8. A process as camd'inclaim 7, in which in -a) leaving group Y is selected from halogen, 4vdroxcy, OCC(0) alkyl, O-alkyi., OSo:a, Iy and OS0 2 arIl ZI U I S. 0 5 0 S OS 'S S 0 0 0* 55 5* S S S 5. .05505 L 3 6.00 *SSS S S S S a. j *5 S OS .5 S S *SeS.S S S SO 5 S S S 55 S 5 5555 I A, Y I Q U V I J 4,1 1 V I I94 U a 9. Aprocess as c~ime leavizg group Z is selec. OSO 2 _a1kyl, h,--7oalkvlsulpOL. 10 A process as claimec substantiallv as herein Cz Examtles. Compounds as lire by a process a~s cl~iimed J 12.. *Pharmaceutical co=( ingre-Idient at. least one C cliimed in aniy one of C12- of a single enantiomer o10 thgrofor apysiologic salt tlher in associat: pharmaceutically acceptal excinients. .13. compositions as cla as herein described in ai 14. Compounds of genera: 25 onelof claims Ito 6or accepotable acid addition therapy- 15, A method of prevent: 30 neurogenarative diseases and of cerebral ischaemii subject Which comprises effective amount of a coi i n any one of claims I. ti acceptable acid addlition. I. in Claim in- whi±Ch in 1b) thb :ed 3Er~u halogen, OSOaryl,I .on& e and sul-phate. I in anly one of claims 7 to.2 lesc cied in any one of the, in claim whoaenever prepared ~any one o3f claims 7 to ~s~tonscot-rising as activxe. ~onmound of f_-'ortula (Iasl L It a. o 6 or 11, in the om dilastereoisoraer or mixtures f a lly acceptable acid addition' oTfwith one or more e carriers, diluents or I *1 II 'I II ,ied in claim 12 substantiall'Y y one of thle Examples. foriila(I)as claimLed inawr L and plays ologi.cally saits thereof Jfor use in 3n, treatvment or reoai r of- an~d conditions, of epilepsy.. of various origins in a Imin.istering to said subject an bound of form~ula as claimed G or III, or a physiologically salt thereof- 97 Abstract The present invention relates to new benzomorphan derivatives of general formula (I) N-CH 2 -C--X-R 2 \R 3 R 8 R O_(I6 processes for their preparation and their use as pharmaceutical compositions for treating cerebra. ischaemia of various origins, epilepsy and se**: 6 0 neurodegenerative diseases.
AU18686/92A 1991-07-02 1992-06-30 Benzomorphan derivatives Expired AU657330B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4121821A DE4121821A1 (en) 1991-07-02 1991-07-02 NEW BENZOMORPHANE AND ITS USE AS A MEDICAMENT
DE4121821 1991-07-02

Publications (2)

Publication Number Publication Date
AU1868692A AU1868692A (en) 1993-01-07
AU657330B2 true AU657330B2 (en) 1995-03-09

Family

ID=6435223

Family Applications (1)

Application Number Title Priority Date Filing Date
AU18686/92A Expired AU657330B2 (en) 1991-07-02 1992-06-30 Benzomorphan derivatives

Country Status (24)

Country Link
EP (1) EP0521422B1 (en)
JP (1) JP3324785B2 (en)
KR (1) KR100251256B1 (en)
AT (1) ATE137749T1 (en)
AU (1) AU657330B2 (en)
CA (1) CA2072814C (en)
CZ (1) CZ286949B6 (en)
DE (2) DE4121821A1 (en)
DK (1) DK0521422T3 (en)
ES (1) ES2086585T3 (en)
FI (1) FI105913B (en)
GR (1) GR3020124T3 (en)
HK (1) HK1003111A1 (en)
HU (1) HU220873B1 (en)
IE (1) IE74400B1 (en)
IL (1) IL102361A (en)
MX (1) MX9203845A (en)
NO (1) NO178263C (en)
NZ (1) NZ243388A (en)
PH (1) PH31430A (en)
SG (1) SG43001A1 (en)
SK (1) SK280776B6 (en)
TW (1) TW214547B (en)
ZA (1) ZA924883B (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19528472A1 (en) * 1995-08-03 1997-02-06 Boehringer Ingelheim Kg New process for the production of norbenzomorphan of an intermediate stage in the production of pharmaceutically valuable benzomorphan derivatives, in particular of (-) - (1R, 5S, S "R) -3'-hydroxy-2- (2-methoxypropyl -) - 5.9.9 -trimethyl-6.7 benzomorphan
DE19740110A1 (en) * 1997-09-12 1999-03-18 Boehringer Ingelheim Pharma New hydroxy substituted benzomorphan derivatives
JPH1196519A (en) * 1997-09-17 1999-04-09 Alps Electric Co Ltd Spin valve type thin-film element and its production
US6136980A (en) * 1998-05-01 2000-10-24 Boehringer Ingelheim Kg Method of preparing norbenzomorphane as an intermediate in the preparation of pharmaceutically useful benzomorphane derivatives, in particular (-)-(1R,5S,2"R)-3'-hydroxy-2-(2-methoxypropyl)-5,9,9-trimethyl-6,7-benzo morphane
DE19826365A1 (en) * 1998-06-12 1999-12-16 Gruenenthal Gmbh Use of benzomorphan derivatives as an analgesic
US6355652B1 (en) 1999-11-27 2002-03-12 Boehringer Ingelheim Pharma Kg Substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocines and their use as pharmaceutical compositions
DE19957156A1 (en) * 1999-11-27 2001-05-31 Boehringer Ingelheim Pharma New amino and fluoro substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocine derivatives useful in treatment of e.g. arrythmias, spasms, ischaemia, pain and neurodegenerative disorders
DE10204276A1 (en) * 2002-02-02 2003-08-07 Boehringer Ingelheim Pharma N-Allyloxyethyl-1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocines and their use as pharmaceuticals
US7501433B2 (en) 2002-05-17 2009-03-10 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
US7923454B2 (en) 2002-05-17 2011-04-12 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
WO2003097608A2 (en) 2002-05-17 2003-11-27 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
US8017622B2 (en) 2003-05-16 2011-09-13 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
AR069545A1 (en) * 2007-11-16 2010-02-03 Boehringer Ingelheim Pharma DERIVATIVES OF ARIL AND HETEROARILCARBONILO OF RELATED BENZOMORPHANS AND RELATED STRUCTURES, PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS, OBTAINING THEMSELVES, THEIR USE IN THE TREATMENT OF DISEASES MEDIATED BY THE INHIBITION OF THE HIDDEN AND DISEASE
US9862726B2 (en) 2013-12-26 2018-01-09 Purdue Pharma L.P. Opioid receptor modulating oxabicyclo[2.2.2]octane morphinans

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU529456B2 (en) * 1978-04-26 1983-06-09 Acf Chemiefarma N.V. 6,7-benzomorphan derivatives

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2828039A1 (en) * 1978-06-26 1980-01-10 Boehringer Sohn Ingelheim 2- (2-ALKOXYETHYL) -2'-HYDROXY-6,7-BENZOMORPHANES THEIR ACID ADDITION SALTS, THESE MEDICINAL PRODUCTS, AND METHOD FOR THE PRODUCTION THEREOF
NL7907800A (en) * 1979-10-23 1981-04-27 Acf Chemiefarma Nv Novel 6,7-benzomorphan derivatives and their acid addition salts, pharmaceutical compositions containing such a compound, and process for the preparation of these compounds and their pharmaceutical compositions.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU529456B2 (en) * 1978-04-26 1983-06-09 Acf Chemiefarma N.V. 6,7-benzomorphan derivatives

Also Published As

Publication number Publication date
FI923050A (en) 1993-01-03
AU1868692A (en) 1993-01-07
CA2072814A1 (en) 1993-01-03
HU220873B1 (en) 2002-06-29
SG43001A1 (en) 1997-10-17
SK207592A3 (en) 1997-01-08
IE922144A1 (en) 1993-01-13
NZ243388A (en) 1994-11-25
ES2086585T3 (en) 1996-07-01
EP0521422B1 (en) 1996-05-08
CZ286949B6 (en) 2000-08-16
CA2072814C (en) 2003-09-23
KR100251256B1 (en) 2000-05-01
IE74400B1 (en) 1997-07-30
ZA924883B (en) 1993-02-24
TW214547B (en) 1993-10-11
FI105913B (en) 2000-10-31
NO922603D0 (en) 1992-07-01
HK1003111A1 (en) 1998-10-09
IL102361A (en) 1997-02-18
DK0521422T3 (en) 1996-06-10
DE4121821A1 (en) 1993-01-14
NO178263B (en) 1995-11-13
NO178263C (en) 1996-02-21
HUT66410A (en) 1994-11-28
JPH05201987A (en) 1993-08-10
JP3324785B2 (en) 2002-09-17
CZ207592A3 (en) 1993-08-11
MX9203845A (en) 1993-01-01
ATE137749T1 (en) 1996-05-15
FI923050A0 (en) 1992-07-01
DE59206212D1 (en) 1996-06-13
EP0521422A1 (en) 1993-01-07
HU9202199D0 (en) 1992-10-28
KR930002321A (en) 1993-02-22
NO922603L (en) 1993-01-04
GR3020124T3 (en) 1996-08-31
IL102361A0 (en) 1993-01-14
PH31430A (en) 1998-11-03
SK280776B6 (en) 2000-07-11

Similar Documents

Publication Publication Date Title
US5731318A (en) Benzomorphan derivatives
AU657330B2 (en) Benzomorphan derivatives
DE60311853T2 (en) NEW 1,4-DIAZABICYCLOALKAN DERIVATIVES, THEIR PREPARATION AND USE
US20030216380A1 (en) Novel gamma secretase inhibitors
DE60309740T2 (en) 1,4-DIZABICYCLO (3,2,2) NONANE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THERAPEUTICAL USE
WO1991004252A1 (en) New esters of thienyl carboxylic acids and amino alcohols, their quaternization products, and manufacture and use of said compounds
DE2305092C2 (en)
EP0052932B1 (en) 2-aminotetralin compounds and pharmaceutical compositions having central alpha1 agonist activity
US3138603A (en) New benzomorphans (methanobenzazocines) and preparation thereof
US3557127A (en) Substituted cyclohexenes,derivatives thereof and processes for obtaining same
CS219943B2 (en) Method of making the racemic and optically unite derivatives of the 1-phenyl-2-cyclohexene-1-alcylamine
US7022729B2 (en) Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists
KR960007864B1 (en) Sulfonyldecahydro-8h-isoquino(2,1-g)(1,6)naphthyridines, optical isomers thereof and related compounds
US4977176A (en) Pilocarpine compounds which are used as pharmaceutical agents
US3830818A (en) Amino quinobenzazepines
DE3630539A1 (en) DERIVATIVES OF 2,3,4,5,6,7-HEXAHYDRO-2,7-METHANO-1,5-BENZOXAZONINE (OR -1,4-BENZOXAZONINE), METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THIS COMPOUND
Weiss et al. Derivatives of Morphine. IV. 1 14-Hydroxymorphine and 14-Hydroxydihydromorphine
US3274248A (en) N-1, 1-bis-[aminophenyl]-propyl-amines and salts thereof
US2820040A (en) Substituted mono-ammonium salts
GB2051054A (en) Pyrazolo (1,5-c) quinazoline derivatives and a process for the preparation thereof
US4281130A (en) Lower-alkyl 4,6,7,8,8a-9-hexahydro-6,9-ethanothieno[3,2-f]indolizine-10-carboxylate
US3359161A (en) Thiaxanthenols, process of producing and anti-tussive compositions thereof
US4233448A (en) 3-Methoxycarbonyl-2-(2-thienyl)-8-azabicyclo[3.2.1]octane-8-acetamide and salts thereof
US4214085A (en) 11-[3-Oxo-ω-(2- and 3-furyl)-lower-alkyl]hexahydro-2,6-methano-3-benzazocines
US4233449A (en) 1-(8-Methyl-2-phenyl(or thienyl)-8-azabicyclo[3.2.1]octan-3-yl) ethanone